Abstract:
This invention relates to methods for the isolation and purification of the recombinantly expressed major protein component of chondroitinase ABC, which is referred to as &#34;chondroitinase I&#34;, from Proteus vulgaris (P. vulgaris). This invention further relates to methods for the isolation and purification of the recombinantly expressed second protein component of chondroitinase ABC, which is referred to as &#34;chondroitinase II&#34;, from P. vulgaris. These methods provide significantly higher yields and purity than those obtained by adapting for the recombinant enzymes the method previously used for isolating and purifying native chondroitinase I enzyme from P. vulgaris.

Description:
This application is a continuation-in-part of U.S. Ser. No. 08/052,206, filed Apr. 23, 1993, now abandoned which is incorporated herein by reference in its entirety. 
    
    
     FIELD OF THE INVENTION 
     This invention relates to methods for the isolation and purification of the recombinantly expressed major protein component of chondroitinase ABC, which is referred to as &#34;chondroitinase I&#34;, from Proteus Vulgaris (P. vulgaris). This invention further relates to methods for the isolation and purification of the recombinantly expressed second protein component of chondroitinase ABC, which is referred to as &#34;chondroitinase II&#34;, from P. vulgaris. These methods provide significantly higher yields and purity than those obtained by adapting for the recombinant enzymes the method previously used for isolating and purifying the native chondroitinase I enzyme from P. vulgaris. 
     BACKGROUND OF THE INVENTION 
     Chondroitinases are enzymes of bacterial origin which have been described as having value in dissolving the cartilage of herniated discs without disturbing the stabilizing collagen components of those discs. 
     Examples of chondroitinase enzymes are chondroitinase ABC, which is produced by the bacterium P. vulgaris, and chondroitinase AC, which is produced by A. aurescens. The chondroitinases function by degrading polysaccharide side chains in protein-polysaccharide complexes, without degrading the protein core. 
     Yamagata et al. describes the purification of the enzyme chondroitinase ABC from extracts of P. vulgaris (Bibliography entry 1). The enzyme selectively degrades the glycosaminoglycans chondroitin-4-sulfate, dermatan sulfate and chondroitin-6-sulfate (also referred to respectively as chondroitin sulfates A, B and C) at pH 8 at higher rates than chondroitin or hyaluronic acid. However, the enzyme did not attack keratosulfate, heparin or heparitin sulfate. 
     Kikuchi et al. describes the purification of glycosaminoglycan degrading enzymes, such as chondroitinase ABC, by fractionating the enzymes by adsorbing a solution containing the enzymes onto an insoluble sulfated polysaccharide carrier and then desorbing the individual enzymes from the carrier (2). 
     Brown describes a method for treating intervertebral disc displacement in mammals, including humans, by injecting into the intervertebral disc space effective amounts of a solution containing chondroitinase ABC (3). The chondroitinase ABC was isolated and purified from extracts of P. vulgaris. This native enzyme material functioned to dissolve cartilage, such as herniated spinal discs. Specifically, the enzyme causes the selective chemonucleolysis of the nucleus pulposus which contains proteoglycans and randomly dispersed collagen fibers. 
     Hageman describes an ophthalmic vitrectomy method for selectively and completely disinserting the ocular vitreous body, epiretinal membranes or fibrocellular membranes from the neural retina, ciliary epithelium and posterior lens surface of the mammalian eye as an adjunct to vitrectomy, by administering to the eye an effective amount of an enzyme which disrupts or degrades chondroitin sulfate proteoglycan localized specifically to sites of vitreoretinal adhesion and thereby permit complete disinsertion of said vitreous body and/or epiretinal membranes (4). The enzyme can be a protease-free glycosaminoglycanase, such as chondroitinase ABC. Hageman utilized chondroitinase ABC obtained from Seikagaku Kogyo Co., Ltd., Tokyo, Japan. 
     In isolating and purifying the chondroitinase ABC enzyme from the Seikagaku Kogyo material, it was noted that there was a correlation between effective preparations of the chondroitinase in vitrectomy procedures and the presence of a second protein having an apparent molecular weight (by SDS-PAGE) slightly greater than that of the major protein component of chondroitinase ABC. The second protein is now designated the &#34;chondroitinase II&#34;, while the major protein component of chondroitinase ABC is referred to as the &#34;chondroitinase I.&#34; The chondroitinase I and II proteins are basic proteins at neutral pH, with similar isoelectric points of 8.30-8.45. Separate purification of the chondroitinase I and II forms of the native enzyme revealed that it was the combination of the two proteins that was active in the surgical vitrectomy rather than either of the proteins individually. 
     Use of the chondroitinase I and II forms of the native enzyme to date has been limited by the small amounts of enzymes obtained from native sources. The production and purification of the native forms of the enzyme has been carried out using fermentations of P. vulgaris in which its substrate has been used as the inducer to initiate production of these forms of the enzyme. A combination of factors, including low levels of synthesis, the cost and availability of the inducer (chondroitin sulfate), and the opportunistically pathogenic nature of P. vulgaris, has resulted in the requirement for a more efficient method of production. In addition, the native forms of the enzyme produced by conventional techniques are subject to degradation by proteases present in the bacterial extract. Therefore, there is a need for methods to isolate and purify a reliable supply of the chondroitinase I and II enzymes free of contaminants in order for the medical applications of the two forms of this enzyme to be evaluated properly and exploited. 
     SUMMARY OF THE INVENTION 
     Accordingly, it is an object of this invention to provide methods for the isolation and purification of the recombinantly expressed chondroitinase I enzyme of P. vulgaris. 
     It is a particular object of this invention to provide methods which result in significantly higher yields and purity of the recombinant chondroitinase I enzyme than those obtained by adapting for the recombinant enzyme the method previously used for isolating and purifying the native chondroitinase I enzyme from P. vulgaris. 
     These objects are achieved through either of two methods described and claimed herein for the chondroitinase I enzyme. The first method comprises the steps of: 
     (a) lysing by homogenization the host cells which express the recombinant chondroitinase I enzyme to release the enzyme into the supernatant; 
     (b) subjecting the supernatant to diafiltration to remove salts and other small molecules; 
     (c) passing the supernatant through an anion exchange resin-containing column; 
     (d) loading the eluate from step (c) to a cation exchange resin-containing column so that the enzyme in the eluate binds to the cation exchange column; and 
     (e) eluting the enzyme bound to the cation exchange column with a solvent capable of releasing the enzyme from the column. 
     In the second method, prior to step (b) of the first method just described, the following two steps are performed: 
     (1) treating the supernatant with an acidic solution to precipitate out the enzyme; and 
     (2) recovering the pellet and then dissolving it in an alkali solution to again place the enzyme in a basic environment. 
     It is a further object of this invention to provide methods for the isolation and purification of the recombinantly expressed chondroitinase II enzyme of P. vulgaris. 
     It is an additional object of this invention to provide methods which result in significantly higher yields and purity of the recombinant chondroitinase II enzyme than those obtained by adapting for the recombinant enzyme the method previously used for isolating and purifying the native chondroitinase I enzyme from P. vulgaris. 
     These objects are achieved through either of two methods described and claimed herein for the chondroitinase II enzyme. The first method comprises the steps of: 
     (a) lysing by homogenization the host cells which express the recombinant chondroitinase I enzyme to release the enzyme into the supernatant; 
     (b) subjecting the supernatant to diafiltration to remove salts and other small molecules; 
     (c) passing the supernatant through an anion exchange resin-containing column; 
     (d) loading the eluate from step (c) to a cation exchange resin-containing column so that the enzyme in the eluate binds to the cation exchange column; 
     (e) obtaining by affinity elution the enzyme bound to the cation exchange column with a solution of chondroitin sulfate, such that the enzyme is co-eluted with the chondroitin sulfate; 
     (f) loading the eluate from step (e) to an anion exchange resin-containing column and eluting the enzyme with a solvent such that the chondroitin sulfate binds to the column; and 
     (g) concentrating the eluate from step (f) and crystallizing out the enzyme from the supernatant which contains an approximately 37 kD contaminant. 
     In the second method, prior to step (b) of the first method just described, the following two steps are performed: 
     (1) treating the supernatant with an acidic solution to precipitate out the enzyme; and 
     (2) recovering the pellet and then dissolving it in an alkali solution to again place the enzyme in a basic environment. 
     Use of the methods of this invention results in significantly higher yields and purity of each recombinant enzyme than those obtained by adapting for each recombinant enzyme the method previously used for isolating and purifying the native chondroitinase I enzyme from P. vulgaris. 
    
    
     BRIEF DESCRIPTION OF THE FIGURES 
     FIG. 1 depicts the elution of the recombinant chondroitinase I enzyme from a cation exchange chromatography column using a sodium chloride gradient. The method used to purify the native enzyme is used here to attempt to purify the recombinant enzyme. The initial fractions at the left do not bind to the column. They contain the majority of the chondroitinase I enzyme activity. The fractions at right containing the enzyme are marked &#34;eluted activity&#34;. The gradient is from 0.0 to 250 mM NaCl. 
     FIG. 2 depicts the elution of the recombinant chondroitinase I enzyme from a cation exchange column, after first passing the supernatant through an anion exchange column, in accordance with a method of this invention. The initial fractions at the left do not bind to the column, and contain only traces of chondroitinase I activity. The fractions at right containing the enzyme are marked &#34;eluted activity&#34;. The gradient is from 0.0 to 250 mMNaCl. 
     FIG. 3 depicts sodium dodecyl sulfate-polyacrylamide gel chromatography (SDS-PAGE) of the recombinant chondroitinase I enzyme before and after the purification methods of this invention are used. In the SDS-PAGE gel photograph, Lane 1 is the enzyme purified using the method of the first embodiment of the invention; Lane 2 is the enzyme purified using the method of the second embodiment of the invention; Lane 3 represents the supernatant from the host cell prior to purification--many other proteins are present; Lane 4 represents the following molecular weight standards: 14.4 kD--lysozyme; 21.5 kD--trypsin inhibitor; 31 kD--carbonic anhydrase; 42.7 kD--ovalbumin; 66.2 kD--bovine serum albumin; 97.4 kD--phosphorylase B; 116 kD--beta-galactosidase; 200 kD--myosin. A single sharp band is seen in Lanes 1 and 2. 
     FIG. 4 depicts SDS-PAGE chromatography of the recombinant chondroitinase II enzyme during various stages of purification using a method of this invention. In the SDS-PAGE gel photograph, Lane 1 is the crude supernatant after diafiltration; Lane 2 the eluate after passage of the supernatant through an anion exchange resin-containing column; Lane 3 is the enzyme after elution through a cation exchange resin-containing column; Lane 4 is the enzyme after elution through a second anion exchange resin-containing column; Lane 5 represents the same molecular weight standards as described for FIG. 3, plus 6.5 kD--aprotinin; Lane 6 is the same as Lane 4, except it is overloaded to show the approximately 37 kD contaminant; Lane 7 is the 37 kD contaminant in the supernatant after crystallization of the chondroitinase II enzyme; Lane 8 is first wash of the crystals; Lane 9 is the second wash of the crystals; Lane 10 is the enzyme in the washed crystals after redissolving in water. 
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     Initial attempts to isolate and purify the recombinant chondroitinase I enzyme do not result in high yields of purified protein. The previous method for isolating and purifying native chondroitinase I from fermentation cultures of P. vulgaris is found to be inappropriate for the recombinant material. 
     The native enzyme is produced by fermentation of a culture of P. vulgaris. The bacterial cells are first recovered from the medium and resuspended in buffer. The cell suspension is then homogenized to lyse the bacterial cells. Then a charged particulate such as Bioacryl (Toso Haas, Philadelphia, Pa.), is added to remove DNA, aggregates and debris from the homogenization step. Next, the solution is brought to 40% saturation of ammonium sulfate to precipitate out undesired proteins. The chondroitinase I remains in solution. 
     The solution is then filtered and the retentate is washed to recover most of the enzyme. The filtrate is concentrated and subjected to diafiltration with a phosphate to remove the salt. 
     The filtrate containing the chondroitinase I is subjected to cation exchange chromatography using a cellulose sulfate column. At pH 7.2, 20 mM sodium phosphate, more than 98% of the chondroitinase I binds to the column. The native chondroitinase I is then eluted from the column using a sodium chloride gradient. 
     The eluted enzyme is then subjected to additional chromatography steps, such as anion exchange and hydrophobic interaction column chromatography. As a result of all of these procedures, chondroitinase I is obtained at a purity of 90-97%. The level of purity is measured by first performing SDS-PAGE. The proteins are stained using Coomassie blue, destained, and the lane on the gel is scanned using a laser beam of wavelength 600 nm. The purity is expressed as the percentage of the total absorbance accounted for by that band. 
     However, the yield of the native protein is only 25-35%. The yield is measured as the remaining activity in the final purified product, expressed as a percentage of the activity at the start (which is taken as 100%). In turn, the activity of the enzyme is based on measuring the release of unsaturated disaccharide from chondroitin sulfate C at 232 nm. 
     This purification method also results in the extensive cleavage of the approximately 110,000 dalton (110 kD) chondroitinase I protein into a 90 kD and an 18 kD fragment. Nonetheless, the two fragments remain non-covalently bound and exhibit chondroitinase I activity. 
     When this procedure is repeated with homogenate from lysed host cells carrying a recombinant plasmid encoding chondroitinase I, significantly poorer results are obtained. Less than 10% of the chondroitinase I binds to the cation exchange column at standard stringent conditions of pH 7.2, 20 mM sodium phosphate. 
     Under less stringent binding conditions of pH 6.8 and 5 mM phosphate, an improvement of binding with one batch of material to 60-90% is observed. However, elution of the recombinant protein with the NaCl gradient gives al broad activity peak, rather than a sharp peak (see FIG. 1). This indicates the product is heterogeneous. Furthermore, in subsequent fermentation batches, the recombinant enzyme binds poorly (1-40%), even using the less stringent binding conditions. Most of these batches are not processed to the end, as there is poor binding. Therefore, their overall recovery is not quantified. 
     Based on these results, it is concluded that the recombinant chondroitinase I enzyme has a reduced basicity compared to the native enzyme, and that the basicity also varies between batches, as well as within the same batch. 
     It is evident that the method used to isolate and purify the native enzyme is not appropriate for the recombinant enzyme. The method produces low yields of protein at high cost. Furthermore, for large batches, large amounts of solvent waste are produced containing large amounts of a nitrogen-containing compound (ammonium sulfate). This is undesirable from an environmental point of view. 
     A hypothesis is then developed to explain these poor results and to provide a basis for developing improved isolation and purification methods. It is known that the native chondroitinase I enzyme is basic at neutral pH. It is therefore assumed that the surface of the enzyme has a net excess of positive charges. 
     Without being bound by this hypothesis, it is believed that, in recombinant expression of the enzyme, the host cell contains or produces small, negatively charged molecules. These negatively charged molecules bind to the enzyme, thereby reducing the number of positive charges on the enzyme. If these negatively charged molecules bind with high enough affinity to copurify with the enzyme, they can cause an alteration of the behavior of the enzyme on the ion exchange column. 
     Support for this hypothesis is provided by the data described below. In general, cation exchange resins bind to proteins better at lower pH&#39;s than higher pH&#39;s. Thus, a protein which is not very basic, and hence does not bind at a high pH, can be made to bind to the cation exchanger by carrying out the operation at a lower pH. At pH 7.2, the native enzyme binds completely to a cation exchange resin. However, the recombinant-derived enzyme, due to the lowered basicity as a result of binding of the negatively charged molecules, does not bind very well (less than 10%). This enzyme can be made to bind up to 70% by using a pH of 6.8 and a lower phosphate concentration (5 mM rather than 20 mM), but heterogeneity and low yield remain great problems. Indeed, only one fermentation results in a 70% binding level; typically, it is much less (less than 10%) even at pH 6.8. This level of binding varies dramatically between different fermentation batches. 
     This hypothesis and a possible solution to the problem are then tested. If negatively charged molecules are attaching non-covalently to chondroitinase I, thus decreasing its basicity, it should be possible to remove these undesired molecules by using a strong, high capacity anion exchange resin. Removal of the negatively charged molecules should then restore the basicity of the enzyme. The enzyme could then be bound to a cation exchange resin and eluted therefrom in pure form at higher yields. 
     Experiments demonstrate that this approach indeed provides a solution to the problem encountered with the isolation and purification of the recombinantly expressed chondroitinase I enzyme. 
     As is discussed below, chondroitinase I is recombinantly expressed in two forms. The enzyme is expressed with a signal peptide, which is then cleaved to produce the mature enzyme. The enzyme is also expressed without a signal peptide, to produce directly the mature enzyme. The two embodiments of this invention which will now be discussed are suitable for use in purifying either of these forms of the enzyme. 
     In the first embodiment of this invention, the host cells which express the recombinant chondroitinase I enzyme are lysed by homogenization to release the enzyme into the supernatant. The supernatant is then subjected to diafiltration to remove salts and other small molecules. However, this step only removes the free, but not the bound form of the negatively charged molecules. The bound form of these charged species is next removed by passing the supernatant through a strong, high capacity anion exchange resin-containing column. An example of such a resin is the Macro-Prep™ High Q resin, which contains a quaternary ammonium functional group (Bio-Rad, Melville, N.Y.). Other strong, high capacity anion exchange columns are also suitable. Weak anion exchangers containing a diethylaminoethyl (DEAE) ligand also are suitable, although they are not as effective. Similarly, low capacity resins are also suitable, although they too are not as effective. The negatively charged molecules bind to the column, while the enzyme passes through the column. It is also found that some unrelated, undesirable proteins also bind to the column. 
     Next, the eluate from the anion exchange column is directly loaded to a cation exchange resin-containing column. Examples of such resins are the S-Sepharose™ (Pharmacia, Piscataway, N.J.) and the Macro-Prep™ High S (Bio-Rad), which contain sulfonic acid functional groups. Each of these two resin-containing columns has SO 3   -  ligands bound thereto in order to facilitate the exchange of cations. Other cation exchange columns are also suitable. The enzyme binds to the column and is then eluted with a solvent capable of releasing the enzyme from the column. 
     Any salt which increases the conductivity of the solution is suitable for elution. Examples of such salts include sodium salts, as well as potassium salts and ammonium salts. An aqueous sodium chloride solution of appropriate concentration is suitable. A gradient, such as 0 to 250 mM sodium chloride is acceptable, as is a step elution using 200 mM sodium chloride. 
     A sharp peak is seen in the sodium chloride gradient elution (FIG. 2). The improvement in enzyme yield over the prior method is striking. The recombinant chondroitinase I enzyme is recovered at a purity of 99% at a yield of 80-90%. 
     The purity of the protein is measured by scanning the bands in SDS-PAGE gels. A 4-20% gradient of acrylamide is used in the development of the gels. The band(s) in each lane of the gel is scanned using the procedure described above. 
     These improvements are related directly to the increase in binding of the enzyme to the cation exchange column which results from first using the anion exchange column. In comparative experiments, when only the cation exchange column is used, only 1% of the enzyme binds to the column. However, when the anion exchange column is used first, over 95% of the enzyme binds to the column. 
     The high purity and yield obtained with the first embodiment of this invention make it more feasible to manufacture the recombinant chondroitinase I enzyme on a large scale. 
     In a second embodiment of this invention, two additional steps are inserted in the method before the diafiltration step of the first embodiment. The supernatant is treated with an acidic solution to precipitate out the desired enzyme. The pellet is recovered and then dissolved in an alkali solution to again place the enzyme in a basic environment. The solution is then subjected to the diafiltration and subsequent steps of the first embodiment of this invention. 
     In comparative experiments with the second embodiment of this invention, when only the cation exchange column is used, only 5% of the enzyme binds to the column. However, when the anion exchange column is used first, essentially 100% of the enzyme binds to the column. The second embodiment provides comparable enzyme purity and yield to the first embodiment of the invention. 
     Acid precipitation removes proteins that remain soluble; however, these proteins are removed anyway by the cation and anion exchange steps that follow (although smaller columns may be used). An advantage of the acid precipitation step is that the sample volume is decreased to about 20% of the original volume after dissolution, and hence can be handled more easily on a large scale. However, the additional acid precipitation and alkali dissolution steps of the second embodiment mean that the second embodiment is more time consuming than the first embodiment. On a manufacturing scale, the marginal improvements in purity and yield provided by the second embodiment may be outweighed by the simpler procedure of the first embodiment, which still provides highly pure chondroitinase I enzyme at high yields. An additional benefit of the two embodiments of the invention is that cleavage of the enzyme into 90 kD and 18 kD fragments is avoided. 
     The high purity of the enzyme produced by the two embodiments of this invention is depicted in FIG. 3. A single sharp band is seen in the SDS-PAGE gel photograph: Lane 1 is the enzyme using the method of the first embodiment; Lane 2 is the enzyme using the method of the second embodiment (Lane 3 represents the supernatant from the host cell prior to purification--many other proteins are present; Lane 4 represents molecular weight standards). 
     The recombinant chondroitinase I enzyme which is purified according to the method of this invention is obtained using genetic engineering techniques. For example, an EcoRI fragment is obtained which contains the gene encoding the enzyme. The DNA sequence of the fragment is 3980 nucleotides in length (SEQ ID NO:1). Translation of the DNA sequence into the putative amino acid sequence reveals a continuous open reading frame (SEQ ID NO:1, nucleotides 119-3181) encoding 1021 amino acids (SEQ ID NO:2). 
     In turn, analysis of the amino acid sequence reveals a 24 residue signal sequence (SEQ ID NO:2, amino acids 1-24), followed by a 997 residue mature (processed) chondroitinase I enzyme (SEQ ID NO:2, amino acids 25-1021). 
     The &#34;18 kD&#34; and &#34;90 kD&#34; fragments are found to be adjacent to each other, with the &#34;18 kD&#34; fragment constituting the first 157 amino acids of the mature protein (SEQ ID NO:2, amino acids 25-181), and the &#34;90 kD&#34; fragment constituting the remaining 840 amino acids of the mature protein (SEQ ID NO:2, amino acids 182-1021). 
     The chondroitinase I enzyme of this invention is expressed using established recombinant DNA methods. Suitable host organisms include bacteria, viruses, yeast, insect or mammalian cell lines, as well as other conventional organisms. The host cell is transformed with a plasmid containing a purified isolated DNA fragment encoding for the chondroitinase I enzyme. The host cell is then cultured under conditions which permit expression of the enzyme by the host cell. In the Examples below, an E. coli host cell is used. However, the isolation and purification methods of this invention are suitable for use with any of the host cell expression systems described above. 
     It may be desirable to subject the chondroitinase I gene to site-directed mutagenesis to introduce unique restriction sites. These permit the gene to be moved, in the correct reading frame, into an expression system which results in expression of the chondroitinase I enzyme at high levels. Such an appropriate host cell is the bacterium E. coli. 
     Two different types of mutagenized constructs are prepared. In the first, the three nucleotides immediately upstream of the initiation codon are changed (SEQ ID NO:1, nucleotides 116-118-CAT instead of ATA) through the use of a mutagenic oligonucleotide (SEQ ID NO:3). The coding region and amino acid sequence encoded by the resulting construct are not changed, and the signal sequence is preserved (SEQ ID NO:1, nucleotides 119-3181; SEQ ID NO:2). 
     In the second construct, the site-directed mutagenesis is carried out at the junction of the signal sequence and the start of the mature protein. A mutagenic oligonucleotide (SEQ ID NO:4) is used which differs at six nucleotides from those of the native sequence (SEQ ID NO:1, nucleotides 185-190). The sequence differences result in (a) the deletion of the signal sequence, and (b) the addition of a methionine residue at the amino-terminus, resulting in a 998 amino acid protein (SEQ ID NO:5, nucleotides 188-3181; SEQ ID NO:6). 
     The gene lacking the signal sequence is inserted into an appropriate expression vector. One such vector is pET-9A (5; Novagen, Madison, Wis.), which is derived from elements of the E. coli bacteriophage T7. The resulting recombinant plasmid is designated pTM49-6. The plasmid is then used to transform an appropriate expression host cell, such as the E. coli B strain BL21/(DE3)/pLysS (6,7). 
     Samples of this E. coli B strain BL21(DE3)/pLysS carrying the recombinant plasmid pTM49-6 have been deposited by Applicant&#39;s Assignee on Feb. 4, 1993, with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, U.S.A., and have been assigned ATCC accession number 69234. 
     The material deposited with the ATCC can also be used in conjunction with the Sequence Listings herein to regenerate the native chondroitinase I gene sequence (SEQ ID NO:1, nucleotides 116-118-ATA is restored), using conventional genetic engineering technology. 
     In the Examples below, the chondroitinase I gene lacking the signal sequence is used. However, the isolation and purification methods of this invention are equally applicable to enzyme expressed by a gene having the native nucleotide sequence, by a gene of the first site-directed mutagenesis construct described above, or by other nucleotide sequences which are biologically equivalent to the native nucleotide sequence. 
     Production of the native chondroitinase I enzyme in P. vulgaris after induction with chondroitin sulfate does not provide a high yield of enzyme; the enzyme represents approximately 0.1% of total protein present. When the recombinant construct with the signal sequence deleted is used in E. coli, approximately 15% of the total protein is the chondroitinase I enzyme. 
     Because of the virtually identical isoelectric points and similar molecular weights for the two proteins, the first method described above for isolating and purifying the recombinant chondroitinase I protein is adapted for isolating and purifying the recombinant chondroitinase II protein, and then modified as will now be described. 
     The need for the modification of the method is based on the fact that the recombinant chondroitinase II protein is expressed at levels approximately several-fold lower than the recombinant chondroitinase I protein; therefore, a more powerful and selective solution is necessary in order to obtain a final chondroitinase II product of a purity equivalent to that obtained for the chondroitinase I protein. 
     The first several steps of the method for the chondroitinase II protein are the same as those used to isolate and purify the chondroitinase I protein. Initially, the host cells which express the recombinant chondroitinase II enzyme are lysed by homogenization to release the enzyme into the supernatant. The supernatant is then subjected to diafiltration to remove salts and other small molecules. However, this step only removes the free, but not the bound form of the negatively charged molecules. The bound form of these charged species is next removed by passing the supernatant through a strong, high capacity anion exchange resin-containing column. An example of such a resin is the Macro-Prep™ High Q resin (Bio-Rad, Melville, N.Y.). Other strong, high capacity anion exchange columns are also suitable. Weak anion exchangers containing a diethylaminoethyl (DEAE) ligand also are suitable, although they are not as effective. Similarly, low capacity resins are also suitable, although they too are not as effective. The negatively charged molecules bind to the column, while the enzyme passes through the column. It is also found that some unrelated, undesirable proteins also bind to the column. 
     Next, the eluate from the anion exchange column is directly loaded to a cation exchange resin-containing column. Examples of such resins are the S-Sepharose™ (Pharmacia, Piscataway, N.J.) and the Macro-Prep™ High S (Bio-Rad). Each of these two resin-containing columns has SO 3   -  ligands bound thereto in order to facilitate the exchange of cations. Other cation exchange columns are also suitable. The enzyme binds to the column, while a significant portion of contaminating proteins elute unbound. 
     At this point, the method diverges from that used for the chondroitinase I protein. Instead of eluting the protein with a non-specific salt solution capable of releasing the enzyme from the cation exchange column, a specific elution using a solution containing chondroitin sulfate is used. 
     This procedure utilizes the affinity the positively charged chondroitinase II protein has for the negatively charged chondroitin sulfate. The affinity is larger than that accounted for by a simple positive and negative interaction alone. It is an enzyme-substrate interaction, which is similar to other specific biological interactions of high affinity, such as antigen-antibody, ligand-receptor, co-factor-protein and inhibitor/activator-protein. Hence, the chondroitin sulfate is able to elute the enzyme from the negatively charged resin. In contrast, the resin-enzyme interaction is a simple positive and negative interaction. 
     Although affinity elution chromatography is as easy to practice as ion-exchange chromatography, the elution is specific, unlike salt elution. Thus, it has the advantages of both affinity chromatography (specificity), as well as ion-exchange chromatography (low cost, ease of operation, reusability). 
     Another advantage is the low conductivity of the eluent (approximately 5% of that of the salt eluent), which allows for further ion-exchange chromatography without a diafiltration/dialysis step, which is required when a salt is used. Note, that this is not a consideration in the method for the chondroitinase I protein, because no further ion-exchange chromatography is needed in order to obtain the purified chondroitinase I protein. 
     There is another reason for not using the method for purifying recombinant chondroitinase I. Chondroitinase II obtained using the chondroitinase I salt elution purification method has poor stability; there is extensive degradation at 4° C. within one week. In contrast, chondroitinase II obtained by affinity elution is stable. The reason for this difference in stability is not known. It is to be noted that chondroitinase I obtained by salt elution is stable. 
     The cation exchange column is next washed with a phosphate buffer to elute unbound proteins, followed by washing with borate buffer to elute loosely bound contaminating proteins and to increase the pH of the resin to that required for the optimal elution of the chondroitinase II protein using the substrate, chondroitin sulfate. 
     Next, a solution of chondroitin sulfate in water, adjusted to pH 9.0, is used to elute the chondroitinase II protein, as a sharp peak (recovery 65%) and at a high purity of approximately 95%. A 1% concentration of chondroitin sulfate is used. A gradient of this solvent is also acceptable. 
     Because the chondroitin sulfate has an affinity for the chondroitinase II protein which is stronger than its affinity for the resin of the column, the chondroitin sulfate co-elutes with the protein. This ensures that only protein which recognizes chondroitin sulfate is eluted, which is desirable, but also means that an additional process step is necessary to separate the chondroitin sulfate from the chondroitinase II protein. 
     In this separation step, the eluate is adjusted to a neutral pH and is loaded as is onto an anion exchange resin-containing column, such as the Macro-Prep™ High Q resin. The column is washed with a phosphate buffer. The chondroitin sulfate binds to the column, while the chondroitinase II protein flows through in the unbound pool with greater than 95% recovery. At this point, the protein is pure, except for the presence of a single minor contaminant of approximately 37 kD. The contaminant may be a breakdown product of the chondroitinase II protein. 
     This contaminant is effectively removed by a crytallization step. The eluate from the anion exchange column is concentrated and the solution is maintained at a reduced temperature such as 4° C. for several days to crystallize out the pure chondroitinase II protein. The supernatant contains the 37 kD contaminant. Centrifugation causes the crystals to form a pellet, while the supernatant with the 37 kD contaminant is removed by pipetting. The crystals are then washed with water. The washed crystals are composed of the chondroitinase II protein at a purity of greater than 99%. 
     In a second embodiment of this invention for the chondroitinase II protein, two additional steps are inserted in the method before the diafiltration step of the first embodiment. The supernatant is treated with an acidic solution to precipitate out the desired enzyme. The pellet is recovered and then dissolved in an alkali solution to again place the enzyme in a basic environment. The solution is then subjected to the diafiltration and subsequent steps of the first embodiment of this invention. 
     Acid precipitation removes proteins that remain soluble; however, these proteins are removed anyway by the cation and anion exchange steps that follow (although smaller columns may be used). An advantage of the acid precipitation step is that the sample volume is decreased compared to the original volume after dissolution, and hence can be handled more easily on a large scale. However, the additional acid precipitation and alkali dissolution steps of the second embodiment mean that the second embodiment is more time consuming than the first embodiment. On a manufacturing scale, the marginal improvements in purity and yield provided by the second embodiment may be outweighed by the simpler procedure of the first embodiment, which still provides highly pure chondroitinase II enzyme at high yields. 
     The recombinant chondroitinase II enzyme which is purified according to the method of this invention is obtained using genetic engineering techniques. For example, a fragment is obtained which contains the gene encoding the enzyme. The DNA sequence of the fragment is 6519 nucleotides in length (SEQ ID NO:7). Translation of the DNA sequence into the putative amino acid sequence reveals an open reading frame (SEQ ID NO:7, nucleotides 3238-6276) encoding 1013 amino acids (SEQ ID NO:8). 
     In turn, analysis of the amino acid sequence reveals a 23 residue signal sequence (SEQ ID NO:8, amino acids 1-23), followed by a 990 residue mature (processed) chondroitinase II enzyme (SEQ ID NO:8, amino acids 24-1013). 
     The chondroitinase II enzyme of this invention is expressed using established recombinant DNA methods. Suitable host organisms include bacteria, viruses, yeast, insect or mammalian cell lines, as well as other conventional organisms. The host cell is transformed with a plasmid containing a purified isolated DNA fragment encoding for the chondroitinase II enzyme. The host cell is then cultured under conditions which permit expression of the enzyme by the host cell. In the Examples below, an E. coli host cell is used. However, the isolation and purification methods of this invention are suitable for use with any of the host cell expression systems described above. 
     The gene encoding the chondroitinase II protein is inserted into an appropriate expression vector. One such vector is pET-9A (5; Novagen, Madison, Wis.), which is derived from elements of the E. coli bacteriophage T7. The resulting recombinant plasmid is designated LP 2  1359. The plasmid is then used to transform an appropriate expression host cell, such as the E. coli B strain BL21/(DE3)/pLysS (6,7). 
     Samples of this E. coli B strain designated TD112, which is BL21(DE3)/pLysS carrying the recombinant plasmid LP 2  1359, have been deposited by Applicant&#39;s Assignee on Apr.  13 , 1993, with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, U.S.A., and have been assigned ATCC accession number 69598. 
     Production of the native chondroitinase II enzyme in P. vulgaris after induction with chondroitin sulfate does not provide a high yield of enzyme; the enzyme represents approximately 0.1% of total protein present. When the recombinant construct is used in E. coli, approximately 2.5% of the total protein is the chondroitinase II enzyme. 
     In order that this invention may be better understood, the following examples are set forth. The examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention. 
     EXAMPLE 1 
     Method For The Isolation And Purification Of The Native Chondroitinase I Enzyme As Adapted To The Recombinant Enzyme 
     The native enzyme is produced by fermentation of a culture of P. vulgaris. The bacterial cells are first recovered from the medium and resuspended in buffer. The cell suspension is then homogenized to lyse the bacterial cells. Then a charged particulate such as 50 ppm Bioacryl (Toso Haas, Philadelphia, Pa.), is added to remove DNA, aggregates and debris from the homogenization step. Next, the solution is brought to 40% saturation of ammonium sulfate to precipitate out undesired proteins. The chondroitinase I remains in solution. 
     The solution is then filtered using a 0.22 micron SP240 filter (Amicon, Beverly, Mass.), and the retentate is washed using nine volumes of 40% ammonium sulfate solution to recover most of the enzyme. The filtrate is concentrated and subjected to diafiltration with a sodium phosphate buffer using a 30 kD filter to remove salts and small molecules. 
     The filtrate containing chondroitinase I is subjected to cation exchange chromatography using a Cellufine™ cellulose sulfate column (Chisso Corporation, distributed by Amicon). At pH 7.2, 20 mM sodium phosphate, more than 98% of the chondroitinase I binds to the column. The native chondroitinase I is then eluted from the column using a 0 to 250 mM sodium chloride gradient, in 20 mM sodium phosphate buffer. 
     The eluted enzyme is then subjected to additional chromatography steps, such as anion exchange and hydrophobic interaction column chromatography. As a result of all of these procedures, chondroitinase I is obtained at a purity of 90-97% as measured by SDS-PAGE scanning (see above). However, the yield of the native protein is only 25-35%, determined as described above. This method also results in the cleavage of the approximately 110 kD chondroitinase I protein into a 90 kD and an 18 kD fragment. Nonetheless, the two fragments remain non-ionically bound and exhibit chondroitinase I activity. 
     When this procedure is repeated with lysed host cells carrying a recombinant plasmid encoding chondroitinase I, significantly poorer results are obtained. Less than 10% of the chondroitinase I binds to the cation exchange column at standard stringent conditions of pH 7.2, 20 mM sodium phosphate. 
     Under less stringent binding conditions of pH 6.8 and 5 mM phosphate, an improvement of binding with one batch of material to 60-90% is observed. However, elution of the recombinant protein with the NaCl gradient gives a broad activity peak, rather than a sharp peak (see FIG. 1). This indicates the product is heterogeneous. Furthermore, in subsequent fermentation batches, the recombinant enzyme binds poorly (1-40%), even using the less stringent binding conditions. Batches that bind poorly are not completely processed, so their overall recovery is not quantified. 
     EXAMPLE 2 
     First Method For The Isolation And Purification Of Recombinant Chondroitinase I According To This Invention 
     As a first step, the host cells which express the recombinant chondroitinase I enzyme are homogenized to lyse the cells. This releases the enzyme into the supernatant. 
     In one embodiment of this invention, the supernatant is first subjected to diafiltration to remove salts and other small molecules. An example of a suitable filter is a spiral wound 30 kD filter made by Amicon (Beverly, Mass.). However, this step only removes the free, but not the bound form of the negatively charged molecules. The bound form of these charged species is removed by passing the supernatant through a strong, high capacity anion exchange resin-containing column. An example of such a resin is the Macro-Prep™ High Q resin (Bio-Rad, Melville, N.Y.). Other strong, high capacity anion exchange columns are also suitable. The negatively charged molecules bind to the column, while the enzyme passes through the column. It is also found that some unrelated, undesirable proteins also bind to the column. 
     Next, the eluate from the anion exchange column is directly loaded to a cation exchange resin-containing column. Examples of such resins are the S-Sepharose™ (Pharmacia, Piscataway, N.J.) and the Macro-Prep™ High S (Bio-Rad). Each of these two resin-containing columns has SO 3   -  ligands bound thereto in order to facilitate the exchange of cations. Other cation exchange columns are also suitable. The enzyme binds to the column and is then eluted with a solvent capable of releasing the enzyme from the column. 
     Any salt which increases the conductivity of the solution is suitable for elution. Examples of such salts include sodium salts, as well as potassium salts and ammonium salts. An aqueous sodium chloride solution of appropriate concentration is suitable. A gradient, such as 0 to 250 mM sodium chloride is acceptable, as is a step elution using 200 mM sodium chloride. 
     A sharp peak is seen in the sodium chloride gradient elution (FIG. 2). The improvement in enzyme yield over the prior method is striking. The recombinant chondroitinase I enzyme is recovered at a purity of 99% at a yield of 80-90%. 
     The purity of the protein is measured by scanning the bands in SDS-PAGE gels. A 4-20% gradient of acrylamide is used in the development of the gels. The band(s) in each lane of the gel is scanned using the procedure described above. 
     These improvements are related directly to the increase in binding of the enzyme to the cation exchange column which results from first using the anion exchange column. In comparative experiments, when only the cation exchange column is used, only 1% of the enzyme binds to the column. However, when the anion exchange column is used first, over 95% of the enzyme binds to the column. 
     EXAMPLE 3 
     Second Method For The Isolation And Purification Of Recombinant Chondroitinase I According To This Invention 
     In the second embodiment of this invention, two additional steps are inserted in the method before the diafiltration step of the first embodiment. The supernatant is treated with an acidic solution, such as 1M acetic acid, bringing the supernatant to a final pH of 4.5, to precipitate out the desired enzyme. The pellet is obtained by centrifugation at 5,000×g for 20 minutes. The pellet is then dissolved in an alkali solution, such as 20-30 mM NaOH, bringing it to a final pH of 9.8. The solution is then subjected to the diafiltration and subsequent steps of the first embodiment of this invention. 
     In comparative experiments with the second embodiment of this invention, when only the cation exchange column is used, only 5% of the enzyme binds to the column. However, when the anion exchange column is used first, essentially 100% of the enzyme binds to the column. The second embodiment provides comparable enzyme purity and yield to the first embodiment of the invention. 
     Acid precipitation removes proteins that remain soluble; however, these proteins are removed anyway by the cation and anion exchange steps that follow (although smaller columns may be used). An advantage of the acid precipitation step is that the sample volume is decreased to about 20% of the original volume after dissolution, and hence can be handled more easily on a large scale. However, the additional acid precipitation and alkali dissolution steps of the second embodiment mean that the second embodiment is more time consuming than the first embodiment. On a manufacturing scale, the marginal improvements in purity and yield provided by the second embodiment may be outweighed by the simpler procedure of the first embodiment, which still provides highly pure enzyme at high yields. 
     The high purity of the recombinant enzyme obtained by the two embodiments of this invention is depicted in FIG. 3. A single sharp band is seen in the SDS-PAGE gel photograph: Lane 1 is the enzyme using the method of the first embodiment; Lane 2 is the enzyme using the method of the second embodiment; Lane 3 represents the supernatant from the host cell prior to purification--many other proteins are present; and Lane 4 represents molecular weight standards. 
     EXAMPLE 4 
     First Method For The Isolation And Purification Of Recombinant Chondroitinase II According To This Invention 
     The initial part of this method is the same as that used for the recombinant chondroitinase I enzyme. As a first step, the host cells which express the recombinant chondroitinase II enzyme are homogenized to lyse the cells. This releases the enzyme into the supernatant. 
     In one embodiment of this invention, the supernatant is first subjected to diafiltration to remove salts and other small molecules. An example of a suitable filter is a spiral wound 30 kD filter made by Amicon (Beverly, Mass.). However, this step only removes the free, but not the bound form of the negatively charged molecules. The bound form of these charged species is removed by passing the supernatant (see the SDS-PAGE gel depicted in FIG. 4, lane 1) through a strong, high capacity anion exchange resin-containing column. An example of such a resin is the Macro-Prep™ High Q resin (Bio-Rad, Melville, N.Y.). Other strong, high capacity anion exchange columns are also suitable. The negatively charged molecules bind to the column, while the enzyme passes through the column with approximately 90% recovery of the enzyme. It is also found that some unrelated, undesirable proteins also bind to the column. 
     Next, the eluate from the anion exchange column (FIG. 4, lane 2) is directly loaded to a cation exchange resin-containing column. Examples of such resins are the S-Sepharose™ (Pharmacia, Piscataway, N.J.) and the Macro-Prep™ High S (Bio-Rad). Each of these two resin-containing columns has SO 3   -  ligands bound thereto in order to facilitate the exchange of cations. Other cation exchange columns are also suitable. The enzyme binds to the column, while a significant portion of contaminating proteins elute unbound. 
     At this point, the method diverges from that used for the chondroitinase I protein. Instead of eluting the protein with a non-specific salt solution capable of releasing the enzyme from the cation exchange column, a specific elution using a solution containing chondroitin sulfate is used. A 1% concentration of chondroitin sulfate is used; however, a gradient of this solvent is also acceptable. The specific chondroitin sulfate solution is preferred to the non-specific salt solution because the recombinant chondroitinase II protein is expressed at levels approximately several-fold lower than the recombinant chondroitinase I protein; therefore, a more powerful and selective solution is necessary in order to obtain a final chondroitinase II product of a purity equivalent to that obtained for the chondroitinase I protein. 
     The cation exchange column is next washed with a phosphate buffer, pH 7.0, to elute unbound proteins, followed by washing with borate buffer, pH 8.5, to elute loosely bound contaminating proteins and to increase the pH of the resin to that required for the optimal elution of the chondroitinase II protein using the substrate, chondroitin sulfate. 
     Next, a 1% solution of chondroitin sulfate in water, adjusted to pH 9.0, is used to elute the chondroitinase II protein, as a sharp peak (recovery 65%) and at a high purity of approximately 95% (FIG. 4, lane 3). However, the chondroitin sulfate has an affinity for the chondroitinase II protein which is stronger than its affinity for the resin of the column, and therefore the chondroitin sulfate co-elutes with the protein. This ensures that only protein which recognizes chondroitin sulfate is eluted, which is desirable, but also means that an additional process step is necessary to separate the chondroitin sulfate from the chondroitinase II protein. 
     In this separation step, the eluate is adjusted to pH 7.0 and is loaded as is onto an anion exchange resin-containing column, such as the Macro-Prep™ High Q resin. The column is washed with a 20 mM phosphate buffer, pH 6.8. The chondroitin sulfate binds to the column, while the chondroitinase II protein flows through in the unbound pool with greater than 95% recovery. At this point, the protein is pure, except for the presence of a single minor contaminant of approximately 37 kD (FIG. 4, lanes 4 and 6). The contaminant may be a breakdown product of the chondroitinase II protein. 
     This contaminant is effectively removed by a crytallization step. The eluate from the anion exchange column is concentrated to 15 mg/ml protein using an Amicon stirred cell with a 30 kD cutoff. The solution is maintained at 4° C. for several days to crystallize out the pure chondroitinase II protein. The supernatant contains the 37 kD contaminant (FIG. 4, lane 7). Centrifugation causes the crystals to form a pellet, while the supernatant with the 37 kD contaminant is removed by pipetting, and the crystals washed twice with water. After the first wash, some of the contaminant remains (FIG. 4, lane 8), but after the second wash, only the chondroitinase II protein is visible (FIG. 4, lane 9). The washed crystals are redissolved in water and exhibit a single protein band on SDS-PAGE, with a purity of greater than 99% (FIG. 4, lane 10). 
     EXAMPLE 5 
     Second Method For The Isolation And Purification Of Recombinant Chondroitinase II According To This Invention 
     In the second embodiment of this invention, two additional steps are inserted in the method for purifying the chondroitinase II enzyme before the diafiltration step of the first embodiment. The supernatant is treated with an acidic solution, such as 1M acetic acid, bringing the supernatant to a final pH of 4.5, to precipitate out the desired enzyme. The pellet is obtained by centrifugation at 5,000×g for 20 minutes. The pellet is then dissolved in an alkali solution, such as 20-30 mM NaOH, bringing it to a final pH of 9.8. The solution is then subjected to the diafiltration and subsequent steps of the first embodiment of this invention. 
     Bibliography 
     1. Yamagata, T., et al., J. Biol. Chem., 243, 1523-1535 (1968). 
     2. Kikuchi, H., et al., U.S. Pat. No. 5,198,355. 
     3. Brown, M. D., U.S. Pat. No. 4,696,816. 
     4. Hageman, G. S., U.S. Pat. No. 5,292,509. 
     5. Studier, F. W., et al., Methods in Enzymology, 185, 60-89 (1990). 
     6. Studier, F. W., and Moffatt, B. A., J. Mol. Biol., 189, 113-130 (1986). 
     7. Moffatt, B. A., and Studier, F. W., Cell, 49, 221-227 (1987). 
     
         __________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 8(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 3980 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 119..3181(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:GGAATTCCATCACTCAATCATTAAATTTAGGCACAACGATGGGCTATCAGCGTTATGACA60AATTTAATGAAGGACGCATTGGTTTCACTGTTAGCCAGCGTTTCTAAGGAGAAAAATA118ATGCCGATATTTCGTTTTACTGCACTTGCAATGACATTGGGGCTATTA166MetProIlePheArgPheThrAlaLeuAlaMetThrLeuGlyLeuLeu151015TCAGCGCCTTATAACGCGATGGCAGCCACCAGCAATCCTGCATTTGAT214SerAlaProTyrAsnAlaMetAlaAlaThrSerAsnProAlaPheAsp202530CCTAAAAATCTGATGCAGTCAGAAATTTACCATTTTGCACAAAATAAC262ProLysAsnLeuMetGlnSerGluIleTyrHisPheAlaGlnAsnAsn354045CCATTAGCAGACTTCTCATCAGATAAAAACTCAATACTAACGTTATCT310ProLeuAlaAspPheSerSerAspLysAsnSerIleLeuThrLeuSer505560GATAAACGTAGCATTATGGGAAACCAATCTCTTTTATGGAAATGGAAA358AspLysArgSerIleMetGlyAsnGlnSerLeuLeuTrpLysTrpLys65707580GGTGGTAGTAGCTTTACTTTACATAAAAAACTGATTGTCCCCACCGAT406GlyGlySerSerPheThrLeuHisLysLysLeuIleValProThrAsp859095AAAGAAGCATCTAAAGCATGGGGACGCTCATCTACCCCCGTTTTCTCA454LysGluAlaSerLysAlaTrpGlyArgSerSerThrProValPheSer100105110TTTTGGCTTTACAATGAAAAACCGATTGATGGTTATCTTACTATCGAT502PheTrpLeuTyrAsnGluLysProIleAspGlyTyrLeuThrIleAsp115120125TTCGGAGAAAAACTCATTTCAACCAGTGAGGCTCAGGCAGGCTTTAAA550PheGlyGluLysLeuIleSerThrSerGluAlaGlnAlaGlyPheLys130135140GTAAAATTAGATTTCACTGGCTGGCGTGCTGTGGGAGTCTCTTTAAAT598ValLysLeuAspPheThrGlyTrpArgAlaValGlyValSerLeuAsn145150155160AACGATCTTGAAAATCGAGAGATGACCTTAAATGCAACCAATACCTCC646AsnAspLeuGluAsnArgGluMetThrLeuAsnAlaThrAsnThrSer165170175TCTGATGGTACTCAAGACAGCATTGGGCGTTCTTTAGGTGCTAAAGTC694SerAspGlyThrGlnAspSerIleGlyArgSerLeuGlyAlaLysVal180185190GATAGTATTCGTTTTAAAGCGCCTTCTAATGTGAGTCAGGGTGAAATC742AspSerIleArgPheLysAlaProSerAsnValSerGlnGlyGluIle195200205TATATCGACCGTATTATGTTTTCTGTCGATGATGCTCGCTACCAATGG790TyrIleAspArgIleMetPheSerValAspAspAlaArgTyrGlnTrp210215220TCTGATTATCAAGTAAAAACTCGCTTATCAGAACCTGAAATTCAATTT838SerAspTyrGlnValLysThrArgLeuSerGluProGluIleGlnPhe225230235240CACAACGTAAAGCCACAACTACCTGTAACACCTGAAAATTTAGCGGCC886HisAsnValLysProGlnLeuProValThrProGluAsnLeuAlaAla245250255ATTGATCTTATTCGCCAACGTCTAATTAATGAATTTGTCGGAGGTGAA934IleAspLeuIleArgGlnArgLeuIleAsnGluPheValGlyGlyGlu260265270AAAGAGACAAACCTCGCATTAGAAGAGAATATCAGCAAATTAAAAAGT982LysGluThrAsnLeuAlaLeuGluGluAsnIleSerLysLeuLysSer275280285GATTTCGATGCTCTTAATATTCACACTTTAGCAAATGGTGGAACGCAA1030AspPheAspAlaLeuAsnIleHisThrLeuAlaAsnGlyGlyThrGln290295300GGCAGACATCTGATCACTGATAAACAAATCATTATTTATCAACCAGAG1078GlyArgHisLeuIleThrAspLysGlnIleIleIleTyrGlnProGlu305310315320AATCTTAACTCCCAAGATAAACAACTATTTGATAATTATGTTATTTTA1126AsnLeuAsnSerGlnAspLysGlnLeuPheAspAsnTyrValIleLeu325330335GGTAATTACACGACATTAATGTTTAATATTAGCCGTGCTTATGTGCTG1174GlyAsnTyrThrThrLeuMetPheAsnIleSerArgAlaTyrValLeu340345350GAAAAAGATCCCACACAAAAGGCGCAACTAAAGCAGATGTACTTATTA1222GluLysAspProThrGlnLysAlaGlnLeuLysGlnMetTyrLeuLeu355360365ATGACAAAGCATTTATTAGATCAAGGCTTTGTTAAAGGGAGTGCTTTA1270MetThrLysHisLeuLeuAspGlnGlyPheValLysGlySerAlaLeu370375380GTGACAACCCATCACTGGGGATACAGTTCTCGTTGGTGGTATATTTCC1318ValThrThrHisHisTrpGlyTyrSerSerArgTrpTrpTyrIleSer385390395400ACGTTATTAATGTCTGATGCACTAAAAGAAGCGAACCTACAAACTCAA1366ThrLeuLeuMetSerAspAlaLeuLysGluAlaAsnLeuGlnThrGln405410415GTTTATGATTCATTACTGTGGTATTCACGTGAGTTTAAAAGTAGTTTT1414ValTyrAspSerLeuLeuTrpTyrSerArgGluPheLysSerSerPhe420425430GATATGAAAGTAAGTGCTGATAGCTCTGATCTAGATTATTTCAATACC1462AspMetLysValSerAlaAspSerSerAspLeuAspTyrPheAsnThr435440445TTATCTCGCCAACATTTAGCCTTATTATTACTAGAGCCTGATGATCAA1510LeuSerArgGlnHisLeuAlaLeuLeuLeuLeuGluProAspAspGln450455460AAGCGTATCAACTTAGTTAATACTTTCAGCCATTATATCACTGGCGCA1558LysArgIleAsnLeuValAsnThrPheSerHisTyrIleThrGlyAla465470475480TTAACGCAAGTGCCACCGGGTGGTAAAGATGGTTTACGCCCTGATGGT1606LeuThrGlnValProProGlyGlyLysAspGlyLeuArgProAspGly485490495ACAGCATGGCGACATGAAGGCAACTATCCGGGCTACTCTTTCCCAGCC1654ThrAlaTrpArgHisGluGlyAsnTyrProGlyTyrSerPheProAla500505510TTTAAAAATGCCTCTCAGCTTATTTATTTATTACGCGATACACCATTT1702PheLysAsnAlaSerGlnLeuIleTyrLeuLeuArgAspThrProPhe515520525TCAGTGGGTGAAAGTGGTTGGAATAACCTGAAAAAAGCGATGGTTTCA1750SerValGlyGluSerGlyTrpAsnAsnLeuLysLysAlaMetValSer530535540GCGTGGATCTACAGTAATCCAGAAGTTGGATTACCGCTTGCAGGAAGA1798AlaTrpIleTyrSerAsnProGluValGlyLeuProLeuAlaGlyArg545550555560CACCCTTTTAACTCACCTTCGTTAAAATCAGTCGCTCAAGGCTATTAC1846HisProPheAsnSerProSerLeuLysSerValAlaGlnGlyTyrTyr565570575TGGCTTGCCATGTCTGCAAAATCATCGCCTGATAAAACACTTGCATCT1894TrpLeuAlaMetSerAlaLysSerSerProAspLysThrLeuAlaSer580585590ATTTATCTTGCGATTAGTGATAAAACACAAAATGAATCAACTGCTATT1942IleTyrLeuAlaIleSerAspLysThrGlnAsnGluSerThrAlaIle595600605TTTGGAGAAACTATTACACCAGCGTCTTTACCTCAAGGTTTCTATGCC1990PheGlyGluThrIleThrProAlaSerLeuProGlnGlyPheTyrAla610615620TTTAATGGCGGTGCTTTTGGTATTCATCGTTGGCAAGATAAAATGGTG2038PheAsnGlyGlyAlaPheGlyIleHisArgTrpGlnAspLysMetVal625630635640ACACTGAAAGCTTATAACACCAATGTTTGGTCATCTGAAATTTATAAC2086ThrLeuLysAlaTyrAsnThrAsnValTrpSerSerGluIleTyrAsn645650655AAAGATAACCGTTATGGCCGTTACCAAAGTCATGGTGTCGCTCAAATA2134LysAspAsnArgTyrGlyArgTyrGlnSerHisGlyValAlaGlnIle660665670GTGAGTAATGGCTCGCAGCTTTCACAGGGCTATCAGCAAGAAGGTTGG2182ValSerAsnGlySerGlnLeuSerGlnGlyTyrGlnGlnGluGlyTrp675680685GATTGGAATAGAATGCAAGGGGCAACCACTATTCACCTTCCTCTTAAA2230AspTrpAsnArgMetGlnGlyAlaThrThrIleHisLeuProLeuLys690695700GACTTAGACAGTCCTAAACCTCATACCTTAATGCAACGTGGAGAGCGT2278AspLeuAspSerProLysProHisThrLeuMetGlnArgGlyGluArg705710715720GGATTTAGCGGAACATCATCCCTTGAAGGTCAATATGGCATGATGGCA2326GlyPheSerGlyThrSerSerLeuGluGlyGlnTyrGlyMetMetAla725730735TTCGATCTTATTTATCCCGCCAATCTTGAGCGTTTTGATCCTAATTTC2374PheAspLeuIleTyrProAlaAsnLeuGluArgPheAspProAsnPhe740745750ACTGCGAAAAAGAGTGTATTAGCCGCTGATAATCACTTAATTTTTATT2422ThrAlaLysLysSerValLeuAlaAlaAspAsnHisLeuIlePheIle755760765GGTAGCAATATAAATAGTAGTGATAAAAATAAAAATGTTGAAACGACC2470GlySerAsnIleAsnSerSerAspLysAsnLysAsnValGluThrThr770775780TTATTCCAACATGCCATTACTCCAACATTAAATACCCTTTGGATTAAT2518LeuPheGlnHisAlaIleThrProThrLeuAsnThrLeuTrpIleAsn785790795800GGACAAAAGATAGAAAACATGCCTTATCAAACAACACTTCAACAAGGT2566GlyGlnLysIleGluAsnMetProTyrGlnThrThrLeuGlnGlnGly805810815GATTGGTTAATTGATAGCAATGGCAATGGTTACTTAATTACTCAAGCA2614AspTrpLeuIleAspSerAsnGlyAsnGlyTyrLeuIleThrGlnAla820825830GAAAAAGTAAATGTAAGTCGCCAACATCAGGTTTCAGCGGAAAATAAA2662GluLysValAsnValSerArgGlnHisGlnValSerAlaGluAsnLys835840845AATCGCCAACCGACAGAAGGAAACTTTAGCTCGGCATGGATCGATCAC2710AsnArgGlnProThrGluGlyAsnPheSerSerAlaTrpIleAspHis850855860AGCACTCGCCCCAAAGATGCCAGTTATGAGTATATGGTCTTTTTAGAT2758SerThrArgProLysAspAlaSerTyrGluTyrMetValPheLeuAsp865870875880GCGACACCTGAAAAAATGGGAGAGATGGCACAAAAATTCCGTGAAAAT2806AlaThrProGluLysMetGlyGluMetAlaGlnLysPheArgGluAsn885890895AATGGGTTATATCAGGTTCTTCGTAAGGATAAAGACGTTCATATTATT2854AsnGlyLeuTyrGlnValLeuArgLysAspLysAspValHisIleIle900905910CTCGATAAACTCAGCAATGTAACGGGATATGCCTTTTATCAGCCAGCA2902LeuAspLysLeuSerAsnValThrGlyTyrAlaPheTyrGlnProAla915920925TCAATTGAAGACAAATGGATCAAAAAGGTTAATAAACCTGCAATTGTG2950SerIleGluAspLysTrpIleLysLysValAsnLysProAlaIleVal930935940ATGACTCATCGACAAAAAGACACTCTTATTGTCAGTGCAGTTACACCT2998MetThrHisArgGlnLysAspThrLeuIleValSerAlaValThrPro945950955960GATTTAAATATGACTCGCCAAAAAGCAGCAACTCCTGTCACCATCAAT3046AspLeuAsnMetThrArgGlnLysAlaAlaThrProValThrIleAsn965970975GTCACGATTAATGGCAAATGGCAATCTGCTGATAAAAATAGTGAAGTG3094ValThrIleAsnGlyLysTrpGlnSerAlaAspLysAsnSerGluVal980985990AAATATCAGGTTTCTGGTGATAACACTGAACTGACGTTTACGAGTTAC3142LysTyrGlnValSerGlyAspAsnThrGluLeuThrPheThrSerTyr99510001005TTTGGTATTCCACAAGAAATCAAACTCTCGCCACTCCCTTGATTTAATC3191PheGlyIleProGlnGluIleLysLeuSerProLeuPro101010151020AAAAGAACGCTCTTGCGTTCCTTTTTTATTTGCAGGAAATCTGATTATGCTAATAAAAAA3251CCCTTTAGCCCACGCGGTTACATTAAGCCTCTGTTTATCATTACCCGCACAAGCATTACC3311CACTCTGTCTCATGAAGCTTTCGGCGATATTTATCTTTTTGAAGGTGAATTACCCAATAC3371CCTTACCACTTCAAATAATAATCAATTATCGCTAAGCAAACAGCATGCTAAAGATGGTGA3431ACAATCACTCAAATGGCAATATCAACCACAAGCAACATTAACACTAAATAATATTGTTAA3491TTACCAAGATGATAAAAATACAGCCACACCACTCACTTTTATGATGTGGATTTATAATGA3551AAAACCTCAATCTTCCCCATTAACGTTAGCATTTAAACAAAATAATAAAATTGCACTAAG3611TTTTAATGCTGAACTTAATTTTACGGGGTGGCGAGGTATTGCTGTTCCTTTTCGTGATAT3671GCAAGGCTCTGCGACAGGTCAACTTGATCAATTAGTGATCACCGCTCCAAACCAAGCCGG3731AACACTCTTTTTTGATCAAATCATCATGAGTGTACCGTTAGACAATCGTTGGGCAGTACC3791TGACTATCAAACACCTTACGTAAATAACGCAGTAAACACGATGGTTAGTAAAAACTGGAG3851TGCATTATTGATGTACGATCAGATGTTTCAAGCCCATTACCCTACTTTAAACTTCGATAC3911TGAATTTCGCGATGACCAAACAGAAATGGCTTCGATTTATCAGCGCTTTGAATATTATCA3971AGGAATTCC3980(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 1021 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:MetProIlePheArgPheThrAlaLeuAlaMetThrLeuGlyLeuLeu151015SerAlaProTyrAsnAlaMetAlaAlaThrSerAsnProAlaPheAsp202530ProLysAsnLeuMetGlnSerGluIleTyrHisPheAlaGlnAsnAsn354045ProLeuAlaAspPheSerSerAspLysAsnSerIleLeuThrLeuSer505560AspLysArgSerIleMetGlyAsnGlnSerLeuLeuTrpLysTrpLys65707580GlyGlySerSerPheThrLeuHisLysLysLeuIleValProThrAsp859095LysGluAlaSerLysAlaTrpGlyArgSerSerThrProValPheSer100105110PheTrpLeuTyrAsnGluLysProIleAspGlyTyrLeuThrIleAsp115120125PheGlyGluLysLeuIleSerThrSerGluAlaGlnAlaGlyPheLys130135140ValLysLeuAspPheThrGlyTrpArgAlaValGlyValSerLeuAsn145150155160AsnAspLeuGluAsnArgGluMetThrLeuAsnAlaThrAsnThrSer165170175SerAspGlyThrGlnAspSerIleGlyArgSerLeuGlyAlaLysVal180185190AspSerIleArgPheLysAlaProSerAsnValSerGlnGlyGluIle195200205TyrIleAspArgIleMetPheSerValAspAspAlaArgTyrGlnTrp210215220SerAspTyrGlnValLysThrArgLeuSerGluProGluIleGlnPhe225230235240HisAsnValLysProGlnLeuProValThrProGluAsnLeuAlaAla245250255IleAspLeuIleArgGlnArgLeuIleAsnGluPheValGlyGlyGlu260265270LysGluThrAsnLeuAlaLeuGluGluAsnIleSerLysLeuLysSer275280285AspPheAspAlaLeuAsnIleHisThrLeuAlaAsnGlyGlyThrGln290295300GlyArgHisLeuIleThrAspLysGlnIleIleIleTyrGlnProGlu305310315320AsnLeuAsnSerGlnAspLysGlnLeuPheAspAsnTyrValIleLeu325330335GlyAsnTyrThrThrLeuMetPheAsnIleSerArgAlaTyrValLeu340345350GluLysAspProThrGlnLysAlaGlnLeuLysGlnMetTyrLeuLeu355360365MetThrLysHisLeuLeuAspGlnGlyPheValLysGlySerAlaLeu370375380ValThrThrHisHisTrpGlyTyrSerSerArgTrpTrpTyrIleSer385390395400ThrLeuLeuMetSerAspAlaLeuLysGluAlaAsnLeuGlnThrGln405410415ValTyrAspSerLeuLeuTrpTyrSerArgGluPheLysSerSerPhe420425430AspMetLysValSerAlaAspSerSerAspLeuAspTyrPheAsnThr435440445LeuSerArgGlnHisLeuAlaLeuLeuLeuLeuGluProAspAspGln450455460LysArgIleAsnLeuValAsnThrPheSerHisTyrIleThrGlyAla465470475480LeuThrGlnValProProGlyGlyLysAspGlyLeuArgProAspGly485490495ThrAlaTrpArgHisGluGlyAsnTyrProGlyTyrSerPheProAla500505510PheLysAsnAlaSerGlnLeuIleTyrLeuLeuArgAspThrProPhe515520525SerValGlyGluSerGlyTrpAsnAsnLeuLysLysAlaMetValSer530535540AlaTrpIleTyrSerAsnProGluValGlyLeuProLeuAlaGlyArg545550555560HisProPheAsnSerProSerLeuLysSerValAlaGlnGlyTyrTyr565570575TrpLeuAlaMetSerAlaLysSerSerProAspLysThrLeuAlaSer580585590IleTyrLeuAlaIleSerAspLysThrGlnAsnGluSerThrAlaIle595600605PheGlyGluThrIleThrProAlaSerLeuProGlnGlyPheTyrAla610615620PheAsnGlyGlyAlaPheGlyIleHisArgTrpGlnAspLysMetVal625630635640ThrLeuLysAlaTyrAsnThrAsnValTrpSerSerGluIleTyrAsn645650655LysAspAsnArgTyrGlyArgTyrGlnSerHisGlyValAlaGlnIle660665670ValSerAsnGlySerGlnLeuSerGlnGlyTyrGlnGlnGluGlyTrp675680685AspTrpAsnArgMetGlnGlyAlaThrThrIleHisLeuProLeuLys690695700AspLeuAspSerProLysProHisThrLeuMetGlnArgGlyGluArg705710715720GlyPheSerGlyThrSerSerLeuGluGlyGlnTyrGlyMetMetAla725730735PheAspLeuIleTyrProAlaAsnLeuGluArgPheAspProAsnPhe740745750ThrAlaLysLysSerValLeuAlaAlaAspAsnHisLeuIlePheIle755760765GlySerAsnIleAsnSerSerAspLysAsnLysAsnValGluThrThr770775780LeuPheGlnHisAlaIleThrProThrLeuAsnThrLeuTrpIleAsn785790795800GlyGlnLysIleGluAsnMetProTyrGlnThrThrLeuGlnGlnGly805810815AspTrpLeuIleAspSerAsnGlyAsnGlyTyrLeuIleThrGlnAla820825830GluLysValAsnValSerArgGlnHisGlnValSerAlaGluAsnLys835840845AsnArgGlnProThrGluGlyAsnPheSerSerAlaTrpIleAspHis850855860SerThrArgProLysAspAlaSerTyrGluTyrMetValPheLeuAsp865870875880AlaThrProGluLysMetGlyGluMetAlaGlnLysPheArgGluAsn885890895AsnGlyLeuTyrGlnValLeuArgLysAspLysAspValHisIleIle900905910LeuAspLysLeuSerAsnValThrGlyTyrAlaPheTyrGlnProAla915920925SerIleGluAspLysTrpIleLysLysValAsnLysProAlaIleVal930935940MetThrHisArgGlnLysAspThrLeuIleValSerAlaValThrPro945950955960AspLeuAsnMetThrArgGlnLysAlaAlaThrProValThrIleAsn965970975ValThrIleAsnGlyLysTrpGlnSerAlaAspLysAsnSerGluVal980985990LysTyrGlnValSerGlyAspAsnThrGluLeuThrPheThrSerTyr99510001005PheGlyIleProGlnGluIleLysLeuSerProLeuPro101010151020(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 48 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:GCCAGCGTTTCTAAGGAGAAAACATATGCCGATATTTCGTTTTACTGC48(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 37 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:GCGCCTTATAACGCGCATATGGCCACCAGCAATCCTG37(2) INFORMATION FOR SEQ ID NO:5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 3980 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 188..3181(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:GGAATTCCATCACTCAATCATTAAATTTAGGCACAACGATGGGCTATCAGCGTTATGACA60AATTTAATGAAGGACGCATTGGTTTCACTGTTAGCCAGCGTTTCTAAGGAGAAAAATAAT120GCCGATATTTCGTTTTACTGCACTTGCAATGACATTGGGGCTATTATCAGCGCCTTATAA180CGCGGATATGGCCACCAGCAATCCTGCATTTGATCCTAAAAATCTGATG229MetAlaThrSerAsnProAlaPheAspProLysAsnLeuMet1510CAGTCAGAAATTTACCATTTTGCACAAAATAACCCATTAGCAGACTTC277GlnSerGluIleTyrHisPheAlaGlnAsnAsnProLeuAlaAspPhe15202530TCATCAGATAAAAACTCAATACTAACGTTATCTGATAAACGTAGCATT325SerSerAspLysAsnSerIleLeuThrLeuSerAspLysArgSerIle354045ATGGGAAACCAATCTCTTTTATGGAAATGGAAAGGTGGTAGTAGCTTT373MetGlyAsnGlnSerLeuLeuTrpLysTrpLysGlyGlySerSerPhe505560ACTTTACATAAAAAACTGATTGTCCCCACCGATAAAGAAGCATCTAAA421ThrLeuHisLysLysLeuIleValProThrAspLysGluAlaSerLys657075GCATGGGGACGCTCATCTACCCCCGTTTTCTCATTTTGGCTTTACAAT469AlaTrpGlyArgSerSerThrProValPheSerPheTrpLeuTyrAsn808590GAAAAACCGATTGATGGTTATCTTACTATCGATTTCGGAGAAAAACTC517GluLysProIleAspGlyTyrLeuThrIleAspPheGlyGluLysLeu95100105110ATTTCAACCAGTGAGGCTCAGGCAGGCTTTAAAGTAAAATTAGATTTC565IleSerThrSerGluAlaGlnAlaGlyPheLysValLysLeuAspPhe115120125ACTGGCTGGCGTGCTGTGGGAGTCTCTTTAAATAACGATCTTGAAAAT613ThrGlyTrpArgAlaValGlyValSerLeuAsnAsnAspLeuGluAsn130135140CGAGAGATGACCTTAAATGCAACCAATACCTCCTCTGATGGTACTCAA661ArgGluMetThrLeuAsnAlaThrAsnThrSerSerAspGlyThrGln145150155GACAGCATTGGGCGTTCTTTAGGTGCTAAAGTCGATAGTATTCGTTTT709AspSerIleGlyArgSerLeuGlyAlaLysValAspSerIleArgPhe160165170AAAGCGCCTTCTAATGTGAGTCAGGGTGAAATCTATATCGACCGTATT757LysAlaProSerAsnValSerGlnGlyGluIleTyrIleAspArgIle175180185190ATGTTTTCTGTCGATGATGCTCGCTACCAATGGTCTGATTATCAAGTA805MetPheSerValAspAspAlaArgTyrGlnTrpSerAspTyrGlnVal195200205AAAACTCGCTTATCAGAACCTGAAATTCAATTTCACAACGTAAAGCCA853LysThrArgLeuSerGluProGluIleGlnPheHisAsnValLysPro210215220CAACTACCTGTAACACCTGAAAATTTAGCGGCCATTGATCTTATTCGC901GlnLeuProValThrProGluAsnLeuAlaAlaIleAspLeuIleArg225230235CAACGTCTAATTAATGAATTTGTCGGAGGTGAAAAAGAGACAAACCTC949GlnArgLeuIleAsnGluPheValGlyGlyGluLysGluThrAsnLeu240245250GCATTAGAAGAGAATATCAGCAAATTAAAAAGTGATTTCGATGCTCTT997AlaLeuGluGluAsnIleSerLysLeuLysSerAspPheAspAlaLeu255260265270AATATTCACACTTTAGCAAATGGTGGAACGCAAGGCAGACATCTGATC1045AsnIleHisThrLeuAlaAsnGlyGlyThrGlnGlyArgHisLeuIle275280285ACTGATAAACAAATCATTATTTATCAACCAGAGAATCTTAACTCCCAA1093ThrAspLysGlnIleIleIleTyrGlnProGluAsnLeuAsnSerGln290295300GATAAACAACTATTTGATAATTATGTTATTTTAGGTAATTACACGACA1141AspLysGlnLeuPheAspAsnTyrValIleLeuGlyAsnTyrThrThr305310315TTAATGTTTAATATTAGCCGTGCTTATGTGCTGGAAAAAGATCCCACA1189LeuMetPheAsnIleSerArgAlaTyrValLeuGluLysAspProThr320325330CAAAAGGCGCAACTAAAGCAGATGTACTTATTAATGACAAAGCATTTA1237GlnLysAlaGlnLeuLysGlnMetTyrLeuLeuMetThrLysHisLeu335340345350TTAGATCAAGGCTTTGTTAAAGGGAGTGCTTTAGTGACAACCCATCAC1285LeuAspGlnGlyPheValLysGlySerAlaLeuValThrThrHisHis355360365TGGGGATACAGTTCTCGTTGGTGGTATATTTCCACGTTATTAATGTCT1333TrpGlyTyrSerSerArgTrpTrpTyrIleSerThrLeuLeuMetSer370375380GATGCACTAAAAGAAGCGAACCTACAAACTCAAGTTTATGATTCATTA1381AspAlaLeuLysGluAlaAsnLeuGlnThrGlnValTyrAspSerLeu385390395CTGTGGTATTCACGTGAGTTTAAAAGTAGTTTTGATATGAAAGTAAGT1429LeuTrpTyrSerArgGluPheLysSerSerPheAspMetLysValSer400405410GCTGATAGCTCTGATCTAGATTATTTCAATACCTTATCTCGCCAACAT1477AlaAspSerSerAspLeuAspTyrPheAsnThrLeuSerArgGlnHis415420425430TTAGCCTTATTATTACTAGAGCCTGATGATCAAAAGCGTATCAACTTA1525LeuAlaLeuLeuLeuLeuGluProAspAspGlnLysArgIleAsnLeu435440445GTTAATACTTTCAGCCATTATATCACTGGCGCATTAACGCAAGTGCCA1573ValAsnThrPheSerHisTyrIleThrGlyAlaLeuThrGlnValPro450455460CCGGGTGGTAAAGATGGTTTACGCCCTGATGGTACAGCATGGCGACAT1621ProGlyGlyLysAspGlyLeuArgProAspGlyThrAlaTrpArgHis465470475GAAGGCAACTATCCGGGCTACTCTTTCCCAGCCTTTAAAAATGCCTCT1669GluGlyAsnTyrProGlyTyrSerPheProAlaPheLysAsnAlaSer480485490CAGCTTATTTATTTATTACGCGATACACCATTTTCAGTGGGTGAAAGT1717GlnLeuIleTyrLeuLeuArgAspThrProPheSerValGlyGluSer495500505510GGTTGGAATAACCTGAAAAAAGCGATGGTTTCAGCGTGGATCTACAGT1765GlyTrpAsnAsnLeuLysLysAlaMetValSerAlaTrpIleTyrSer515520525AATCCAGAAGTTGGATTACCGCTTGCAGGAAGACACCCTTTTAACTCA1813AsnProGluValGlyLeuProLeuAlaGlyArgHisProPheAsnSer530535540CCTTCGTTAAAATCAGTCGCTCAAGGCTATTACTGGCTTGCCATGTCT1861ProSerLeuLysSerValAlaGlnGlyTyrTyrTrpLeuAlaMetSer545550555GCAAAATCATCGCCTGATAAAACACTTGCATCTATTTATCTTGCGATT1909AlaLysSerSerProAspLysThrLeuAlaSerIleTyrLeuAlaIle560565570AGTGATAAAACACAAAATGAATCAACTGCTATTTTTGGAGAAACTATT1957SerAspLysThrGlnAsnGluSerThrAlaIlePheGlyGluThrIle575580585590ACACCAGCGTCTTTACCTCAAGGTTTCTATGCCTTTAATGGCGGTGCT2005ThrProAlaSerLeuProGlnGlyPheTyrAlaPheAsnGlyGlyAla595600605TTTGGTATTCATCGTTGGCAAGATAAAATGGTGACACTGAAAGCTTAT2053PheGlyIleHisArgTrpGlnAspLysMetValThrLeuLysAlaTyr610615620AACACCAATGTTTGGTCATCTGAAATTTATAACAAAGATAACCGTTAT2101AsnThrAsnValTrpSerSerGluIleTyrAsnLysAspAsnArgTyr625630635GGCCGTTACCAAAGTCATGGTGTCGCTCAAATAGTGAGTAATGGCTCG2149GlyArgTyrGlnSerHisGlyValAlaGlnIleValSerAsnGlySer640645650CAGCTTTCACAGGGCTATCAGCAAGAAGGTTGGGATTGGAATAGAATG2197GlnLeuSerGlnGlyTyrGlnGlnGluGlyTrpAspTrpAsnArgMet655660665670CAAGGGGCAACCACTATTCACCTTCCTCTTAAAGACTTAGACAGTCCT2245GlnGlyAlaThrThrIleHisLeuProLeuLysAspLeuAspSerPro675680685AAACCTCATACCTTAATGCAACGTGGAGAGCGTGGATTTAGCGGAACA2293LysProHisThrLeuMetGlnArgGlyGluArgGlyPheSerGlyThr690695700TCATCCCTTGAAGGTCAATATGGCATGATGGCATTCGATCTTATTTAT2341SerSerLeuGluGlyGlnTyrGlyMetMetAlaPheAspLeuIleTyr705710715CCCGCCAATCTTGAGCGTTTTGATCCTAATTTCACTGCGAAAAAGAGT2389ProAlaAsnLeuGluArgPheAspProAsnPheThrAlaLysLysSer720725730GTATTAGCCGCTGATAATCACTTAATTTTTATTGGTAGCAATATAAAT2437ValLeuAlaAlaAspAsnHisLeuIlePheIleGlySerAsnIleAsn735740745750AGTAGTGATAAAAATAAAAATGTTGAAACGACCTTATTCCAACATGCC2485SerSerAspLysAsnLysAsnValGluThrThrLeuPheGlnHisAla755760765ATTACTCCAACATTAAATACCCTTTGGATTAATGGACAAAAGATAGAA2533IleThrProThrLeuAsnThrLeuTrpIleAsnGlyGlnLysIleGlu770775780AACATGCCTTATCAAACAACACTTCAACAAGGTGATTGGTTAATTGAT2581AsnMetProTyrGlnThrThrLeuGlnGlnGlyAspTrpLeuIleAsp785790795AGCAATGGCAATGGTTACTTAATTACTCAAGCAGAAAAAGTAAATGTA2629SerAsnGlyAsnGlyTyrLeuIleThrGlnAlaGluLysValAsnVal800805810AGTCGCCAACATCAGGTTTCAGCGGAAAATAAAAATCGCCAACCGACA2677SerArgGlnHisGlnValSerAlaGluAsnLysAsnArgGlnProThr815820825830GAAGGAAACTTTAGCTCGGCATGGATCGATCACAGCACTCGCCCCAAA2725GluGlyAsnPheSerSerAlaTrpIleAspHisSerThrArgProLys835840845GATGCCAGTTATGAGTATATGGTCTTTTTAGATGCGACACCTGAAAAA2773AspAlaSerTyrGluTyrMetValPheLeuAspAlaThrProGluLys850855860ATGGGAGAGATGGCACAAAAATTCCGTGAAAATAATGGGTTATATCAG2821MetGlyGluMetAlaGlnLysPheArgGluAsnAsnGlyLeuTyrGln865870875GTTCTTCGTAAGGATAAAGACGTTCATATTATTCTCGATAAACTCAGC2869ValLeuArgLysAspLysAspValHisIleIleLeuAspLysLeuSer880885890AATGTAACGGGATATGCCTTTTATCAGCCAGCATCAATTGAAGACAAA2917AsnValThrGlyTyrAlaPheTyrGlnProAlaSerIleGluAspLys895900905910TGGATCAAAAAGGTTAATAAACCTGCAATTGTGATGACTCATCGACAA2965TrpIleLysLysValAsnLysProAlaIleValMetThrHisArgGln915920925AAAGACACTCTTATTGTCAGTGCAGTTACACCTGATTTAAATATGACT3013LysAspThrLeuIleValSerAlaValThrProAspLeuAsnMetThr930935940CGCCAAAAAGCAGCAACTCCTGTCACCATCAATGTCACGATTAATGGC3061ArgGlnLysAlaAlaThrProValThrIleAsnValThrIleAsnGly945950955AAATGGCAATCTGCTGATAAAAATAGTGAAGTGAAATATCAGGTTTCT3109LysTrpGlnSerAlaAspLysAsnSerGluValLysTyrGlnValSer960965970GGTGATAACACTGAACTGACGTTTACGAGTTACTTTGGTATTCCACAA3157GlyAspAsnThrGluLeuThrPheThrSerTyrPheGlyIleProGln975980985990GAAATCAAACTCTCGCCACTCCCTTGATTTAATCAAAAGAACGCTCTTGCGTTC3211GluIleLysLeuSerProLeuPro995CTTTTTTATTTGCAGGAAATCTGATTATGCTAATAAAAAACCCTTTAGCCCACGCGGTTA3271CATTAAGCCTCTGTTTATCATTACCCGCACAAGCATTACCCACTCTGTCTCATGAAGCTT3331TCGGCGATATTTATCTTTTTGAAGGTGAATTACCCAATACCCTTACCACTTCAAATAATA3391ATCAATTATCGCTAAGCAAACAGCATGCTAAAGATGGTGAACAATCACTCAAATGGCAAT3451ATCAACCACAAGCAACATTAACACTAAATAATATTGTTAATTACCAAGATGATAAAAATA3511CAGCCACACCACTCACTTTTATGATGTGGATTTATAATGAAAAACCTCAATCTTCCCCAT3571TAACGTTAGCATTTAAACAAAATAATAAAATTGCACTAAGTTTTAATGCTGAACTTAATT3631TTACGGGGTGGCGAGGTATTGCTGTTCCTTTTCGTGATATGCAAGGCTCTGCGACAGGTC3691AACTTGATCAATTAGTGATCACCGCTCCAAACCAAGCCGGAACACTCTTTTTTGATCAAA3751TCATCATGAGTGTACCGTTAGACAATCGTTGGGCAGTACCTGACTATCAAACACCTTACG3811TAAATAACGCAGTAAACACGATGGTTAGTAAAAACTGGAGTGCATTATTGATGTACGATC3871AGATGTTTCAAGCCCATTACCCTACTTTAAACTTCGATACTGAATTTCGCGATGACCAAA3931CAGAAATGGCTTCGATTTATCAGCGCTTTGAATATTATCAAGGAATTCC3980(2) INFORMATION FOR SEQ ID NO:6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 998 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:MetAlaThrSerAsnProAlaPheAspProLysAsnLeuMetGlnSer151015GluIleTyrHisPheAlaGlnAsnAsnProLeuAlaAspPheSerSer202530AspLysAsnSerIleLeuThrLeuSerAspLysArgSerIleMetGly354045AsnGlnSerLeuLeuTrpLysTrpLysGlyGlySerSerPheThrLeu505560HisLysLysLeuIleValProThrAspLysGluAlaSerLysAlaTrp65707580GlyArgSerSerThrProValPheSerPheTrpLeuTyrAsnGluLys859095ProIleAspGlyTyrLeuThrIleAspPheGlyGluLysLeuIleSer100105110ThrSerGluAlaGlnAlaGlyPheLysValLysLeuAspPheThrGly115120125TrpArgAlaValGlyValSerLeuAsnAsnAspLeuGluAsnArgGlu130135140MetThrLeuAsnAlaThrAsnThrSerSerAspGlyThrGlnAspSer145150155160IleGlyArgSerLeuGlyAlaLysValAspSerIleArgPheLysAla165170175ProSerAsnValSerGlnGlyGluIleTyrIleAspArgIleMetPhe180185190SerValAspAspAlaArgTyrGlnTrpSerAspTyrGlnValLysThr195200205ArgLeuSerGluProGluIleGlnPheHisAsnValLysProGlnLeu210215220ProValThrProGluAsnLeuAlaAlaIleAspLeuIleArgGlnArg225230235240LeuIleAsnGluPheValGlyGlyGluLysGluThrAsnLeuAlaLeu245250255GluGluAsnIleSerLysLeuLysSerAspPheAspAlaLeuAsnIle260265270HisThrLeuAlaAsnGlyGlyThrGlnGlyArgHisLeuIleThrAsp275280285LysGlnIleIleIleTyrGlnProGluAsnLeuAsnSerGlnAspLys290295300GlnLeuPheAspAsnTyrValIleLeuGlyAsnTyrThrThrLeuMet305310315320PheAsnIleSerArgAlaTyrValLeuGluLysAspProThrGlnLys325330335AlaGlnLeuLysGlnMetTyrLeuLeuMetThrLysHisLeuLeuAsp340345350GlnGlyPheValLysGlySerAlaLeuValThrThrHisHisTrpGly355360365TyrSerSerArgTrpTrpTyrIleSerThrLeuLeuMetSerAspAla370375380LeuLysGluAlaAsnLeuGlnThrGlnValTyrAspSerLeuLeuTrp385390395400TyrSerArgGluPheLysSerSerPheAspMetLysValSerAlaAsp405410415SerSerAspLeuAspTyrPheAsnThrLeuSerArgGlnHisLeuAla420425430LeuLeuLeuLeuGluProAspAspGlnLysArgIleAsnLeuValAsn435440445ThrPheSerHisTyrIleThrGlyAlaLeuThrGlnValProProGly450455460GlyLysAspGlyLeuArgProAspGlyThrAlaTrpArgHisGluGly465470475480AsnTyrProGlyTyrSerPheProAlaPheLysAsnAlaSerGlnLeu485490495IleTyrLeuLeuArgAspThrProPheSerValGlyGluSerGlyTrp500505510AsnAsnLeuLysLysAlaMetValSerAlaTrpIleTyrSerAsnPro515520525GluValGlyLeuProLeuAlaGlyArgHisProPheAsnSerProSer530535540LeuLysSerValAlaGlnGlyTyrTyrTrpLeuAlaMetSerAlaLys545550555560SerSerProAspLysThrLeuAlaSerIleTyrLeuAlaIleSerAsp565570575LysThrGlnAsnGluSerThrAlaIlePheGlyGluThrIleThrPro580585590AlaSerLeuProGlnGlyPheTyrAlaPheAsnGlyGlyAlaPheGly595600605IleHisArgTrpGlnAspLysMetValThrLeuLysAlaTyrAsnThr610615620AsnValTrpSerSerGluIleTyrAsnLysAspAsnArgTyrGlyArg625630635640TyrGlnSerHisGlyValAlaGlnIleValSerAsnGlySerGlnLeu645650655SerGlnGlyTyrGlnGlnGluGlyTrpAspTrpAsnArgMetGlnGly660665670AlaThrThrIleHisLeuProLeuLysAspLeuAspSerProLysPro675680685HisThrLeuMetGlnArgGlyGluArgGlyPheSerGlyThrSerSer690695700LeuGluGlyGlnTyrGlyMetMetAlaPheAspLeuIleTyrProAla705710715720AsnLeuGluArgPheAspProAsnPheThrAlaLysLysSerValLeu725730735AlaAlaAspAsnHisLeuIlePheIleGlySerAsnIleAsnSerSer740745750AspLysAsnLysAsnValGluThrThrLeuPheGlnHisAlaIleThr755760765ProThrLeuAsnThrLeuTrpIleAsnGlyGlnLysIleGluAsnMet770775780ProTyrGlnThrThrLeuGlnGlnGlyAspTrpLeuIleAspSerAsn785790795800GlyAsnGlyTyrLeuIleThrGlnAlaGluLysValAsnValSerArg805810815GlnHisGlnValSerAlaGluAsnLysAsnArgGlnProThrGluGly820825830AsnPheSerSerAlaTrpIleAspHisSerThrArgProLysAspAla835840845SerTyrGluTyrMetValPheLeuAspAlaThrProGluLysMetGly850855860GluMetAlaGlnLysPheArgGluAsnAsnGlyLeuTyrGlnValLeu865870875880ArgLysAspLysAspValHisIleIleLeuAspLysLeuSerAsnVal885890895ThrGlyTyrAlaPheTyrGlnProAlaSerIleGluAspLysTrpIle900905910LysLysValAsnLysProAlaIleValMetThrHisArgGlnLysAsp915920925ThrLeuIleValSerAlaValThrProAspLeuAsnMetThrArgGln930935940LysAlaAlaThrProValThrIleAsnValThrIleAsnGlyLysTrp945950955960GlnSerAlaAspLysAsnSerGluValLysTyrGlnValSerGlyAsp965970975AsnThrGluLeuThrPheThrSerTyrPheGlyIleProGlnGluIle980985990LysLeuSerProLeuPro995(2) INFORMATION FOR SEQ ID NO:7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 6519 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 3238..6276(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:GGAATTCCATCACTCAATCATTAAATTTAGGCACAACGATGGGCTATCAGCGTTATGACA60AATTTAATGAAGGACGCATTGGTTTCACTGTTAGCCAGCGTTTCTAAGGAGAAAAATAAT120GCCGATATTTCGTTTTACTGCACTTGCAATGACATTGGGGCTATTATCAGCGCCTTATAA180CGCGATGGCAGCCACCAGCAATCCTGCATTTGATCCTAAAAATCTGATGCAGTCAGAAAT240TTACCATTTTGCACAAAATAACCCATTAGCAGACTTCTCATCAGATAAAAACTCAATACT300AACGTTATCTGATAAACGTAGCATTATGGGAAACCAATCTCTTTTATGGAAATGGAAAGG360TGGTAGTAGCTTTACTTTACATAAAAAACTGATTGTCCCCACCGATAAAGAAGCATCTAA420AGCATGGGGACGCTCATCTACCCCCGTTTTCTCATTTTGGCTTTACAATGAAAAACCGAT480TGATGGTTATCTTACTATCGATTTCGGAGAAAAACTCATTTCAACCAGTGAGGCTCAGGC540AGGCTTTAAAGTAAAATTAGATTTCACTGGCTGGCGTGCTGTGGGAGTCTCTTTAAATAA600CGATCTTGAAAATCGAGAGATGACCTTAAATGCAACCAATACCTCCTCTGATGGTACTCA660AGACAGCATTGGGCGTTCTTTAGGTGCTAAAGTCGATAGTATTCGTTTTAAAGCGCCTTC720TAATGTGAGTCAGGGTGAAATCTATATCGACCGTATTATGTTTTCTGTCGATGATGCTCG780CTACCAATGGTCTGATTATCAAGTAAAAACTCGCTTATCAGAACCTGAAATTCAATTTCA840CAACGTAAAGCCACAACTACCTGTAACACCTGAAAATTTAGCGGCCATTGATCTTATTCG900CCAACGTCTAATTAATGAATTTGTCGGAGGTGAAAAAGAGACAAACCTCGCATTAGAAGA960GAATATCAGCAAATTAAAAAGTGATTTCGATGCTCTTAATATTCACACTTTAGCAAATGG1020TGGAACGCAAGGCAGACATCTGATCACTGATAAACAAATCATTATTTATCAACCAGAGAA1080TCTTAACTCCCAAGATAAACAACTATTTGATAATTATGTTATTTTAGGTAATTACACGAC1140ATTAATGTTTAATATTAGCCGTGCTTATGTGCTGGAAAAAGATCCCACACAAAAGGCGCA1200ACTAAAGCAGATGTACTTATTAATGACAAAGCATTTATTAGATCAAGGCTTTGTTAAAGG1260GAGTGCTTTAGTGACAACCCATCACTGGGGATACAGTTCTCGTTGGTGGTATATTTCCAC1320GTTATTAATGTCTGATGCACTAAAAGAAGCGAACCTACAAACTCAAGTTTATGATTCATT1380ACTGTGGTATTCACGTGAGTTTAAAAGTAGTTTTGATATGAAAGTAAGTGCTGATAGCTC1440TGATCTAGATTATTTCAATACCTTATCTCGCCAACATTTAGCCTTATTATTACTAGAGCC1500TGATGATCAAAAGCGTATCAACTTAGTTAATACTTTCAGCCATTATATCACTGGCGCATT1560AACGCAAGTGCCACCGGGTGGTAAAGATGGTTTACGCCCTGATGGTACAGCATGGCGACA1620TGAAGGCAACTATCCGGGCTACTCTTTCCCAGCCTTTAAAAATGCCTCTCAGCTTATTTA1680TTTATTACGCGATACACCATTTTCAGTGGGTGAAAGTGGTTGGAATAACCTGAAAAAAGC1740GATGGTTTCAGCGTGGATCTACAGTAATCCAGAAGTTGGATTACCGCTTGCAGGAAGACA1800CCCTTTTAACTCACCTTCGTTAAAATCAGTCGCTCAAGGCTATTACTGGCTTGCCATGTC1860TGCAAAATCATCGCCTGATAAAACACTTGCATCTATTTATCTTGCGATTAGTGATAAAAC1920ACAAAATGAATCAACTGCTATTTTTGGAGAAACTATTACACCAGCGTCTTTACCTCAAGG1980TTTCTATGCCTTTAATGGCGGTGCTTTTGGTATTCATCGTTGGCAAGATAAAATGGTGAC2040ACTGAAAGCTTATAACACCAATGTTTGGTCATCTGAAATTTATAACAAAGATAACCGTTA2100TGGCCGTTACCAAAGTCATGGTGTCGCTCAAATAGTGAGTAATGGCTCGCAGCTTTCACA2160GGGCTATCAGCAAGAAGGTTGGGATTGGAATAGAATGCAAGGGGCAACCACTATTCACCT2220TCCTCTTAAAGACTTAGACAGTCCTAAACCTCATACCTTAATGCAACGTGGAGAGCGTGG2280ATTTAGCGGAACATCATCCCTTGAAGGTCAATATGGCATGATGGCATTCGATCTTATTTA2340TCCCGCCAATCTTGAGCGTTTTGATCCTAATTTCACTGCGAAAAAGAGTGTATTAGCCGC2400TGATAATCACTTAATTTTTATTGGTAGCAATATAAATAGTAGTGATAAAAATAAAAATGT2460TGAAACGACCTTATTCCAACATGCCATTACTCCAACATTAAATACCCTTTGGATTAATGG2520ACAAAAGATAGAAAACATGCCTTATCAAACAACACTTCAACAAGGTGATTGGTTAATTGA2580TAGCAATGGCAATGGTTACTTAATTACTCAAGCAGAAAAAGTAAATGTAAGTCGCCAACA2640TCAGGTTTCAGCGGAAAATAAAAATCGCCAACCGACAGAAGGAAACTTTAGCTCGGCATG2700GATCGATCACAGCACTCGCCCCAAAGATGCCAGTTATGAGTATATGGTCTTTTTAGATGC2760GACACCTGAAAAAATGGGAGAGATGGCACAAAAATTCCGTGAAAATAATGGGTTATATCA2820GGTTCTTCGTAAGGATAAAGACGTTCATATTATTCTCGATAAACTCAGCAATGTAACGGG2880ATATGCCTTTTATCAGCCAGCATCAATTGAAGACAAATGGATCAAAAAGGTTAATAAACC2940TGCAATTGTGATGACTCATCGACAAAAAGACACTCTTATTGTCAGTGCAGTTACACCTGA3000TTTAAATATGACTCGCCAAAAAGCAGCAACTCCTGTCACCATCAATGTCACGATTAATGG3060CAAATGGCAATCTGCTGATAAAAATAGTGAAGTGAAATATCAGGTTTCTGGTGATAACAC3120TGAACTGACGTTTACGAGTTACTTTGGTATTCCACAAGAAATCAAACTCTCGCCACTCCC3180TTGATTTAATCAAAAGAACGCTCTTGCGTTCCTTTTTTATTTGCAGGAAATCTGATT3237ATGCTAATAAAAAACCCTTTAGCCCACGCGGTTACATTAAGCCTCTGT3285MetLeuIleLysAsnProLeuAlaHisAlaValThrLeuSerLeuCys151015TTATCATTACCCGCACAAGCATTACCCACTCTGTCTCATGAAGCTTTC3333LeuSerLeuProAlaGlnAlaLeuProThrLeuSerHisGluAlaPhe202530GGCGATATTTATCTTTTTGAAGGTGAATTACCCAATACCCTTACCACT3381GlyAspIleTyrLeuPheGluGlyGluLeuProAsnThrLeuThrThr354045TCAAATAATAATCAATTATCGCTAAGCAAACAGCATGCTAAAGATGGT3429SerAsnAsnAsnGlnLeuSerLeuSerLysGlnHisAlaLysAspGly505560GAACAATCACTCAAATGGCAATATCAACCACAAGCAACATTAACACTA3477GluGlnSerLeuLysTrpGlnTyrGlnProGlnAlaThrLeuThrLeu65707580AATAATATTGTTAATTACCAAGATGATAAAAATACAGCCACACCACTC3525AsnAsnIleValAsnTyrGlnAspAspLysAsnThrAlaThrProLeu859095ACTTTTATGATGTGGATTTATAATGAAAAACCTCAATCTTCCCCATTA3573ThrPheMetMetTrpIleTyrAsnGluLysProGlnSerSerProLeu100105110ACGTTAGCATTTAAACAAAATAATAAAATTGCACTAAGTTTTAATGCT3621ThrLeuAlaPheLysGlnAsnAsnLysIleAlaLeuSerPheAsnAla115120125GAACTTAATTTTACGGGGTGGCGAGGTATTGCTGTTCCTTTTCGTGAT3669GluLeuAsnPheThrGlyTrpArgGlyIleAlaValProPheArgAsp130135140ATGCAAGGCTCTGCGACAGGTCAACTTGATCAATTAGTGATCACCGCT3717MetGlnGlySerAlaThrGlyGlnLeuAspGlnLeuValIleThrAla145150155160CCAAACCAAGCCGGAACACTCTTTTTTGATCAAATCATCATGAGTGTA3765ProAsnGlnAlaGlyThrLeuPhePheAspGlnIleIleMetSerVal165170175CCGTTAGACAATCGTTGGGCAGTACCTGACTATCAAACACCTTACGTA3813ProLeuAspAsnArgTrpAlaValProAspTyrGlnThrProTyrVal180185190AATAACGCAGTAAACACGATGGTTAGTAAAAACTGGAGTGCATTATTG3861AsnAsnAlaValAsnThrMetValSerLysAsnTrpSerAlaLeuLeu195200205ATGTACGATCAGATGTTTCAAGCCCATTACCCTACTTTAAACTTCGAT3909MetTyrAspGlnMetPheGlnAlaHisTyrProThrLeuAsnPheAsp210215220ACTGAATTTCGCGATGACCAAACAGAAATGGCTTCGATTTATCAGCGC3957ThrGluPheArgAspAspGlnThrGluMetAlaSerIleTyrGlnArg225230235240TTTGAATATTATCAAGGAATTCGTAGTGATAAAAAAATTACTCCAGAT4005PheGluTyrTyrGlnGlyIleArgSerAspLysLysIleThrProAsp245250255ATGCTAGATAAACATTTAGCATTATGGGAAAAATTGGTGTTAACACAA4053MetLeuAspLysHisLeuAlaLeuTrpGluLysLeuValLeuThrGln260265270CACGCTGATGGCTCAATCACAGGAAAAGCCCTTGATCACCCTAACCGG4101HisAlaAspGlySerIleThrGlyLysAlaLeuAspHisProAsnArg275280285CAACATTTTATGAAAGTCGAAGGTGTATTTAGTGAGGGGACTCAAAAA4149GlnHisPheMetLysValGluGlyValPheSerGluGlyThrGlnLys290295300GCATTACTTGATGCCAATATGCTAAGAGATGTGGGCAAAACGCTTCTT4197AlaLeuLeuAspAlaAsnMetLeuArgAspValGlyLysThrLeuLeu305310315320CAAACTGCTATTTACTTGCGTAGCGATTCATTATCAGCAACTGATAGA4245GlnThrAlaIleTyrLeuArgSerAspSerLeuSerAlaThrAspArg325330335AAAAAATTAGAAGAGCGCTATTTATTAGGTACTCGTTATGTCCTTGAA4293LysLysLeuGluGluArgTyrLeuLeuGlyThrArgTyrValLeuGlu340345350CAAGGTTTTACACGAGGAAGTGGTTATCAAATTATTACTCATGTTGGT4341GlnGlyPheThrArgGlySerGlyTyrGlnIleIleThrHisValGly355360365TACCAAACCAGAGAACTTTTTGATGCATGGTTTATTGGCCGTCATGTT4389TyrGlnThrArgGluLeuPheAspAlaTrpPheIleGlyArgHisVal370375380CTTGCAAAAAATAACCTTTTAGCCCCCACTCAACAAGCTATGATGTGG4437LeuAlaLysAsnAsnLeuLeuAlaProThrGlnGlnAlaMetMetTrp385390395400TACAACGCCACAGGACGTATTTTTGAAAAAAATAATGAAATTGTTGAT4485TyrAsnAlaThrGlyArgIlePheGluLysAsnAsnGluIleValAsp405410415GCAAATGTCGATATTCTCAATACTCAATTGCAATGGATGATAAAAAGC4533AlaAsnValAspIleLeuAsnThrGlnLeuGlnTrpMetIleLysSer420425430TTATTGATGCTACCGGATTATCAACAACGTCAACAAGCCTTAGCGCAA4581LeuLeuMetLeuProAspTyrGlnGlnArgGlnGlnAlaLeuAlaGln435440445CTGCAAAGTTGGCTAAATAAAACCATTCTAAGCTCAAAAGGTGTTGCT4629LeuGlnSerTrpLeuAsnLysThrIleLeuSerSerLysGlyValAla450455460GGCGGTTTCAAATCTGATGGTTCTATTTTTCACCATTCACAACATTAC4677GlyGlyPheLysSerAspGlySerIlePheHisHisSerGlnHisTyr465470475480CCCGCTTATGCTAAAGATGCATTTGGTGGTTTAGCACCCAGTGTTTAT4725ProAlaTyrAlaLysAspAlaPheGlyGlyLeuAlaProSerValTyr485490495GCATTAAGTGATTCACCTTTTCGCTTATCTACTTCAGCACATGAGCGT4773AlaLeuSerAspSerProPheArgLeuSerThrSerAlaHisGluArg500505510TTAAAAGATGTTTTGTTAAAAATGCGGATCTACACCAAAGAGACACAA4821LeuLysAspValLeuLeuLysMetArgIleTyrThrLysGluThrGln515520525ATTCCTGTGGTATTAAGTGGTCGTCATCCAACTGGGTTGCATAAAATA4869IleProValValLeuSerGlyArgHisProThrGlyLeuHisLysIle530535540GGGATCGCGCCATTTAAATGGATGGCATTAGCAGGAACCCCAGATGGC4917GlyIleAlaProPheLysTrpMetAlaLeuAlaGlyThrProAspGly545550555560AAACAAAAGTTAGATACCACATTATCCGCCGCTTATGCAAAATTAGAC4965LysGlnLysLeuAspThrThrLeuSerAlaAlaTyrAlaLysLeuAsp565570575AACAAAACGCATTTTGAAGGCATTAACGCTGAAAGTGAGCCAGTCGGC5013AsnLysThrHisPheGluGlyIleAsnAlaGluSerGluProValGly580585590GCATGGGCAATGAATTATGCATCAATGGCAATACAACGAAGAGCATCG5061AlaTrpAlaMetAsnTyrAlaSerMetAlaIleGlnArgArgAlaSer595600605ACCCAATCACCACAACAAAGCTGGCTCGCCATAGCGCGCGGTTTTAGC5109ThrGlnSerProGlnGlnSerTrpLeuAlaIleAlaArgGlyPheSer610615620CGTTATCTTGTTGGTAATGAAAGCTATGAAAATAACAACCGTTATGGT5157ArgTyrLeuValGlyAsnGluSerTyrGluAsnAsnAsnArgTyrGly625630635640CGTTATTTACAATATGGACAATTGGAAATTATTCCAGCTGATTTAACT5205ArgTyrLeuGlnTyrGlyGlnLeuGluIleIleProAlaAspLeuThr645650655CAATCAGGGTTTAGCCATGCTGGATGGGATTGGAATAGATATCCAGGT5253GlnSerGlyPheSerHisAlaGlyTrpAspTrpAsnArgTyrProGly660665670ACAACAACTATTCATCTTCCCTATAACGAACTTGAAGCAAAACTTAAT5301ThrThrThrIleHisLeuProTyrAsnGluLeuGluAlaLysLeuAsn675680685CAATTACCTGCTGCAGGTATTGAAGAAATGTTGCTTTCAACAGAAAGT5349GlnLeuProAlaAlaGlyIleGluGluMetLeuLeuSerThrGluSer690695700TACTCTGGTGCAAATACCCTTAATAATAACAGTATGTTTGCCATGAAA5397TyrSerGlyAlaAsnThrLeuAsnAsnAsnSerMetPheAlaMetLys705710715720TTACACGGTCACAGTAAATATCAACAACAAAGCTTAAGGGCAAATAAA5445LeuHisGlyHisSerLysTyrGlnGlnGlnSerLeuArgAlaAsnLys725730735TCCTATTTCTTATTTGATAATAGAGTTATTGCTTTAGGCTCAGGTATT5493SerTyrPheLeuPheAspAsnArgValIleAlaLeuGlySerGlyIle740745750GAAAATGATGATAAACAACATACGACCGAAACAACACTATTCCAGTTT5541GluAsnAspAspLysGlnHisThrThrGluThrThrLeuPheGlnPhe755760765GCCGTCCCTAAATTACAGTCAGTGATCATTAATGGCAAAAAGGTAAAT5589AlaValProLysLeuGlnSerValIleIleAsnGlyLysLysValAsn770775780CAATTAGATACTCAATTAACTTTAAATAATGCAGATACATTAATTGAT5637GlnLeuAspThrGlnLeuThrLeuAsnAsnAlaAspThrLeuIleAsp785790795800CCTGCCGGCAATTTATATAAGCTCACTAAAGGACAAACTGTAAAATTT5685ProAlaGlyAsnLeuTyrLysLeuThrLysGlyGlnThrValLysPhe805810815AGTTATCAAAAACAACATTCACTTGATGATAGAAATTCAAAACCAACA5733SerTyrGlnLysGlnHisSerLeuAspAspArgAsnSerLysProThr820825830GAACAATTATTTGCAACAGCTGTTATTTCTCATGGTAAGGCACCGAGT5781GluGlnLeuPheAlaThrAlaValIleSerHisGlyLysAlaProSer835840845AATGAAAATTATGAATATGCAATAGCTATCGAAGCACAAAATAATAAA5829AsnGluAsnTyrGluTyrAlaIleAlaIleGluAlaGlnAsnAsnLys850855860GCTCCCGAATACACAGTATTACAACATAATGATCAGCTCCATGCGGTA5877AlaProGluTyrThrValLeuGlnHisAsnAspGlnLeuHisAlaVal865870875880AAAGATAAAATAACCCAAGAAGAGGGATATGCTTTTTTTGAAGCCACT5925LysAspLysIleThrGlnGluGluGlyTyrAlaPhePheGluAlaThr885890895AAGTTAAAATCAGCGGATGCAACATTATTATCCAGTGATGCGCCGGTT5973LysLeuLysSerAlaAspAlaThrLeuLeuSerSerAspAlaProVal900905910ATGGTCATGGCTAAAATACAAAATCAGCAATTAACATTAAGTATTGTT6021MetValMetAlaLysIleGlnAsnGlnGlnLeuThrLeuSerIleVal915920925AATCCTGATTTAAATTTATATCAAGGTAGAGAAAAAGATCAATTTGAT6069AsnProAspLeuAsnLeuTyrGlnGlyArgGluLysAspGlnPheAsp930935940GATAAAGGTAATCAAATCGAAGTTAGTGTTTATTCTCGTCATTGGCTT6117AspLysGlyAsnGlnIleGluValSerValTyrSerArgHisTrpLeu945950955960ACAGCAGAATCGCAATCAACAAATAGTACTATTACCGTAAAAGGAATA6165ThrAlaGluSerGlnSerThrAsnSerThrIleThrValLysGlyIle965970975TGGAAATTAACGACACCTCAACCCGGTGTTATTATTAAGCACCACAAT6213TrpLysLeuThrThrProGlnProGlyValIleIleLysHisHisAsn980985990AACAACACTCTTATTACGACAACAACCATACAGGCAACACCTACTGTT6261AsnAsnThrLeuIleThrThrThrThrIleGlnAlaThrProThrVal99510001005ATTAATTTAGTTAAGTAAATTTCGTAACTTTTAAACTAAAGAGTCTCGACATAAA6316IleAsnLeuValLys1010AATATCGAGACTCTTTTTATTAAAAAATTAAAAACAAGTTAACGAATGAATTAATTATTT6376GAAAAATAAAAAATAAATCGATAGCTTTATTATTGATAATAAATGTGTTGTGCTCAATGG6436TTATTTTGTTATTCTCTGCGCGGATGCTTGGATCAATCTGGTTCAAGCATATCGCAAGCA6496CCAGAACGAAAAAAGCCCCGGGT6519(2) INFORMATION FOR SEQ ID NO:8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 1013 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:MetLeuIleLysAsnProLeuAlaHisAlaValThrLeuSerLeuCys151015LeuSerLeuProAlaGlnAlaLeuProThrLeuSerHisGluAlaPhe202530GlyAspIleTyrLeuPheGluGlyGluLeuProAsnThrLeuThrThr354045SerAsnAsnAsnGlnLeuSerLeuSerLysGlnHisAlaLysAspGly505560GluGlnSerLeuLysTrpGlnTyrGlnProGlnAlaThrLeuThrLeu65707580AsnAsnIleValAsnTyrGlnAspAspLysAsnThrAlaThrProLeu859095ThrPheMetMetTrpIleTyrAsnGluLysProGlnSerSerProLeu100105110ThrLeuAlaPheLysGlnAsnAsnLysIleAlaLeuSerPheAsnAla115120125GluLeuAsnPheThrGlyTrpArgGlyIleAlaValProPheArgAsp130135140MetGlnGlySerAlaThrGlyGlnLeuAspGlnLeuValIleThrAla145150155160ProAsnGlnAlaGlyThrLeuPhePheAspGlnIleIleMetSerVal165170175ProLeuAspAsnArgTrpAlaValProAspTyrGlnThrProTyrVal180185190AsnAsnAlaValAsnThrMetValSerLysAsnTrpSerAlaLeuLeu195200205MetTyrAspGlnMetPheGlnAlaHisTyrProThrLeuAsnPheAsp210215220ThrGluPheArgAspAspGlnThrGluMetAlaSerIleTyrGlnArg225230235240PheGluTyrTyrGlnGlyIleArgSerAspLysLysIleThrProAsp245250255MetLeuAspLysHisLeuAlaLeuTrpGluLysLeuValLeuThrGln260265270HisAlaAspGlySerIleThrGlyLysAlaLeuAspHisProAsnArg275280285GlnHisPheMetLysValGluGlyValPheSerGluGlyThrGlnLys290295300AlaLeuLeuAspAlaAsnMetLeuArgAspValGlyLysThrLeuLeu305310315320GlnThrAlaIleTyrLeuArgSerAspSerLeuSerAlaThrAspArg325330335LysLysLeuGluGluArgTyrLeuLeuGlyThrArgTyrValLeuGlu340345350GlnGlyPheThrArgGlySerGlyTyrGlnIleIleThrHisValGly355360365TyrGlnThrArgGluLeuPheAspAlaTrpPheIleGlyArgHisVal370375380LeuAlaLysAsnAsnLeuLeuAlaProThrGlnGlnAlaMetMetTrp385390395400TyrAsnAlaThrGlyArgIlePheGluLysAsnAsnGluIleValAsp405410415AlaAsnValAspIleLeuAsnThrGlnLeuGlnTrpMetIleLysSer420425430LeuLeuMetLeuProAspTyrGlnGlnArgGlnGlnAlaLeuAlaGln435440445LeuGlnSerTrpLeuAsnLysThrIleLeuSerSerLysGlyValAla450455460GlyGlyPheLysSerAspGlySerIlePheHisHisSerGlnHisTyr465470475480ProAlaTyrAlaLysAspAlaPheGlyGlyLeuAlaProSerValTyr485490495AlaLeuSerAspSerProPheArgLeuSerThrSerAlaHisGluArg500505510LeuLysAspValLeuLeuLysMetArgIleTyrThrLysGluThrGln515520525IleProValValLeuSerGlyArgHisProThrGlyLeuHisLysIle530535540GlyIleAlaProPheLysTrpMetAlaLeuAlaGlyThrProAspGly545550555560LysGlnLysLeuAspThrThrLeuSerAlaAlaTyrAlaLysLeuAsp565570575AsnLysThrHisPheGluGlyIleAsnAlaGluSerGluProValGly580585590AlaTrpAlaMetAsnTyrAlaSerMetAlaIleGlnArgArgAlaSer595600605ThrGlnSerProGlnGlnSerTrpLeuAlaIleAlaArgGlyPheSer610615620ArgTyrLeuValGlyAsnGluSerTyrGluAsnAsnAsnArgTyrGly625630635640ArgTyrLeuGlnTyrGlyGlnLeuGluIleIleProAlaAspLeuThr645650655GlnSerGlyPheSerHisAlaGlyTrpAspTrpAsnArgTyrProGly660665670ThrThrThrIleHisLeuProTyrAsnGluLeuGluAlaLysLeuAsn675680685GlnLeuProAlaAlaGlyIleGluGluMetLeuLeuSerThrGluSer690695700TyrSerGlyAlaAsnThrLeuAsnAsnAsnSerMetPheAlaMetLys705710715720LeuHisGlyHisSerLysTyrGlnGlnGlnSerLeuArgAlaAsnLys725730735SerTyrPheLeuPheAspAsnArgValIleAlaLeuGlySerGlyIle740745750GluAsnAspAspLysGlnHisThrThrGluThrThrLeuPheGlnPhe755760765AlaValProLysLeuGlnSerValIleIleAsnGlyLysLysValAsn770775780GlnLeuAspThrGlnLeuThrLeuAsnAsnAlaAspThrLeuIleAsp785790795800ProAlaGlyAsnLeuTyrLysLeuThrLysGlyGlnThrValLysPhe805810815SerTyrGlnLysGlnHisSerLeuAspAspArgAsnSerLysProThr820825830GluGlnLeuPheAlaThrAlaValIleSerHisGlyLysAlaProSer835840845AsnGluAsnTyrGluTyrAlaIleAlaIleGluAlaGlnAsnAsnLys850855860AlaProGluTyrThrValLeuGlnHisAsnAspGlnLeuHisAlaVal865870875880LysAspLysIleThrGlnGluGluGlyTyrAlaPhePheGluAlaThr885890895LysLeuLysSerAlaAspAlaThrLeuLeuSerSerAspAlaProVal900905910MetValMetAlaLysIleGlnAsnGlnGlnLeuThrLeuSerIleVal915920925AsnProAspLeuAsnLeuTyrGlnGlyArgGluLysAspGlnPheAsp930935940AspLysGlyAsnGlnIleGluValSerValTyrSerArgHisTrpLeu945950955960ThrAlaGluSerGlnSerThrAsnSerThrIleThrValLysGlyIle965970975TrpLysLeuThrThrProGlnProGlyValIleIleLysHisHisAsn980985990AsnAsnThrLeuIleThrThrThrThrIleGlnAlaThrProThrVal99510001005IleAsnLeuValLys1010__________________________________________________________________________